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2. INTRODUCTION 
2.1 CANCER INCIDENCE AND MORTALITY IN 2018 
According to the statistics obtained from the official website of the European Cancer 
Information System (ECIS) almost 4 million new cancer cases, excluding non-melanoma skin 
cancer, have been registered in 2018 (ECIS, 2019).  These data has been confirmed also by 
Ferlay et al. in their publication from November 2018. The highest occurrence of cancer was 
identified in the breast (522 513 cases), followed by colorectal (499 667 cases), lung (470 039 
cases) and prostate (449 761 cases) in Europe.  Moreover, almost 2 million of deaths due to 
this disease have been registered. These data show, that cancer is a serious issue and requires 
scientific interest.  
Although cancer is in the interest to the whole scientific world, it is still difficult to make it 
fully curable. The problem is the variety of cancer types. Each case must be considered 
individually. Moreover, chemotherapeutic resistances occur, what makes the whole process of 
treatment even more complicated and challenging. However, every year there are new therapies 
introduced in this area of medicine. The survival rate in Europe increased significantly in 
comparison to the previous years. According to Quaresma et al., 10 years survival rate 
increased from 24% in 1970’s to 49.8% in 2010 (Quaresma et al., 2015). 
 
2.2 HALLMARKS OF CANCER 
 Cancer cells develop a lot of mechanisms to avoid cellular death and to divide infinitely. They 
can avoid drug induced death, among others, due to self-sufficiency in induction of growth 
factors release. Moreover, they can ignore anti-proliferative and apoptotic signaling pathways. 
What is also helpful to survive in a drug environment is unlimited replicative potential. These 
events lead to infinite growth of those cells.  
Cancer cells can also manipulate the environment to force the organism to build a vascular 
network in their neighborhood, to receive enough cytokines, growth factors, oxygen and 
nutrients necessary for survival. What is more, cancer cells have the potential to migrate and 
invade organs through the blood stream (Hanahan & Weinberg, 2000). Those properties are 
supporting the process of cancer spreading within the organism. Figure 2.1 represents all the 
8 
 
hallmarks of cancer, namely: sustained angiogenesis, limitless growth potential as well as self-
sufficiency in growth factors, metastatic and invasive potential and avoidance of the anti-
growth and anti-apoptotic signaling. 
 
Figure 2.1. Hallmarks of cancer. 
 
2.3 RESISTANCE TO THE COMMON CHEMOTHERAPEUTICS AS A SERIOUS ISSUE 
One of the biggest problems in cancer therapy is the ability of cells to form resistance towards 
chemotherapeutics. A lot of evidence has shown a multitude of drug resistance mechanisms for 
both - general multi-drug resistance factors and factors specific for one class of drugs 
(Wijdeven et al., 2016).  
Resistance to chemotherapeutics can be divided into two broad categories: intrinsic or acquired. 
We can assign a resistance to an intrinsic type when cancer cells are resistant towards the 
chemotherapeutic even before the treatment starts. It can be caused by overexpression of 
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resistance mediating factors, what results in an ineffective therapy (Holohan et al., 2013). 
Acquired resistance occurs, when cells form the ability to survive in the presence of a drug. 
There are many ways for cancer cells to overcome a chemotherapy. Cancer cells can either 
activate pro-survival signaling or form a mechanism to protect themselves from induction of 
apoptosis or drug effect. There is a lot of limiting steps before a drug can cause a cellular 
damage. First limitation is the drug acquirement. Next, it can be either inactivated or the 
alteration of the drug target can occur. When the drug is already active, the cells can adapt to 
the new environment or defend themselves through the impairment of apoptosis process 
(Figure 2.2).  
 
Figure 2.2. General principles of drug resistance. First limiting step of the therapy is the drug 
acquirement, next factor is a limited drug activation (either through drug inactivation within 
the cell or alteration in a drug target); even if drug is activated, cells can adapt to the new 
environment or lead to the dysfunctions in apoptosis process. 
 
Despite a very good development of cancer treatments, there is still a great problem with an 
insufficient response towards chemotherapeutics. Therefore, combinatorial treatments become 
more and more popular. The purpose of the combinatorial therapy is either to re-sensitize 
cancer cells towards common therapeutics or to decrease the dose of drugs to minimalize the 
side effects. The main rationale behind the combination of more than one drug is to inhibit 
more than one signaling pathway involved in carcinogenesis, therefore obtaining a synergistic 
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effect of the treatment. It has been shown before in various cancer types that this approach is 
successful (Chen & Lahav, 2016). However, the knowledge about the pharmacodynamics, 
pharmacokinetics and the drugs mechanism of action often remain not fully elucidated. Thus, 
there is a need to investigate those processes and to deepen the knowledge in this certain topic. 
 
2.4 RE-SENSITIZATION OF CANCEROUS CELLS TOWARDS TREATMENT 
THROUGH INDUCTION OF ER-STRESS  
The endoplasmic reticulum is an organelle in eukaryotic cells, which takes part in the process 
of protein synthesis, folding, modification and secretion. It is broadly known, that ER 
homeostasis is impaired when carcinogenesis occurs. When the function of ER is blocked 
the ER overflows with immature and defective proteins. This situation is called ER stress. This 
leads to the activation of the unfolded protein response (UPR). The aim of this process is to 
reduce the amount of defective proteins. UPR consist of three defense mechanisms. The 
first one is the arrest of further protein synthesis in the ribosomes. The second one is the repair 
of defective proteins by ER-resident molecular chaperone mobilization. The third one is the 
elimination and degradation of defective proteins from the ER what is called ER-associated 
degradation (ERAD) (Kaneko et al., 2017).  
It has been shown previously, that targeting the UPR and the ER stress gives good results in 
re-sensitization of resistant cancerous cells towards the chemotherapeutics (Dufey et al., 2015). 
Therefore, there is the need to look for drugs targeting the proteins connected to ER 
homeostasis maintenance and to apply them in combinatorial therapies. 
 
2.5 SMALL MOLECULES – T8 AND PS89 
A screening of the commercially available compound library, in terms of chemo-sensitization 
of cancer cells towards Etoposide treatment, has identified T8 as a promising candidate. A 
subsequent proteomic analysis has revealed, that the main target of T8 is the protein disulfate 
isomerase (PDI). The family of PDIs is known as the chaperone proteins and they are involved 
in the maintenance of the ER homeostasis (Lee & Lee, 2017). Moreover, the interaction 
between T8 and PDI was reversible, what made this drug very attractive for further 
investigation (Eirich et al., 2014). 
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 As PDI is a protein required for ER homeostasis maintenance, it has been already shown as an 
interesting target for chemo-sensitization of cancer cells towards Etoposide induced apoptosis 
(Xu et al, 2012; Vatolin et al., 2016). However, the interaction of investigated compounds with 
PDI was not reversible, what reduced their potential in combinatorial treatment approach. 
Therefore, there was a need for further analysis of substances that are able to interact with PDI.  
PS89 has been synthesized as an analogue of T8. The modification has been introduced within 
two benzene rings (R1 and R2). The structures of all derivatives are shown in Figure 2.3 Out of 
six synthesized molecules PS89 has shown the highest potential in induction of Etoposide 
mediated apoptosis in Acute Lymphoblastic Leukemia (ALL) cell line - Jurkat. The 
modification in this molecule consisted of a replacement of fluorine in R1 by an azide group 
(Eirich et al., 2014). 
 
 
Figure 2.3. The structures of T8 derivatives and the IC50 values in µM in comparison to T8 
itself. The figure has been adapted from Eirich et al., 2014. 
 
Surprisingly, what was shown by Dr. Fabian Koczian in his doctoral thesis, PDI was not 
involved in the chemo-sensitizing effect of PS89. Therefore, the Activity-based Protein 
Profiling (ABPP) was conduct and identified a B cell receptor - associated protein (BAP31) as 
one of the interaction partners of PS89.  
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2.6 FUNCTION OF B CELL RECEPTOR - ASSOCIATED PROTEIN (BAP31) PROTEIN 
Bap31 and its homologue Bap29 were originally discovered as B cell receptor-associated 
proteins. It is an integral ER membrane protein with one cytoplasmic and three transmembrane 
domains. It has two identical caspase recognition sites at D164 and D238 that are preferentially 
cleaved by caspase-8. Therefore, upon the apoptotic stimuli, BAP31 can be cleaved into its p20 
form which remains in the cellular membrane. (Kim et al., 1994; Breckenridge et al., 2003; 
Figure 2.4.). 
 
 
Figure 2.4. The putative structure of BAP31 and its cleavage product upon the apoptotic 
stimuli and Caspase-8 cleavage. Figure adapted from Breckenridge et al., 2003. 
 
BAP31 is a protein broadly expressed within a cell. According to the GeneCards the subcellular 
localizations shown in green are derived from database annotations, automatic text mining of 
the biomedical literature, and sequence-based predictions. The confidence of each association 
is signified by stars, where 5 is the highest confidence and 1 is the lowest. Therefore, we can 
conclude that it is very likely to find BAP31 in the plasma membrane as well as in the ER and 
cytosol. However, so far BAP31 was not seen in the nucleus, lysosomes, endosomes or 
peroxisomes (Figure 2.5.). 
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Figure 2.5. BAP31 expression within the mammalian cell. Figure adapted from GeneCards 
(https://www.genecards.org/cgi-bin/carddisp.pl?gene=BCAP31) 
 
According to the function of BAP31, it was shown to be involved in the process of induction 
of apoptosis. Wang et al. have shown that a mitochondrial fission protein - Fission 1 homologue 
(Fis1), transduces the apoptotic signal from ER to mitochondria through an interaction with 
BAP31 (Wang et al., 2011). Moreover, Nguyen et al. proved, that the induction of Fas - 
mediated apoptosis leads to the activation of Caspase-8, what results in the cleavage of BAP31, 
loss of mitochondrial membrane potential (ΔΨm) and, finally, cytochrome c release to the 
cytoplasm (Nguyen et al., 2000; Figure 2.6.). The same schema has been confirmed in the 
different settings and elucidated to the detail (Breckenridge et al., 2003; Iwasawa et al., 2011, 
Grimm, 2012). 
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Figure 2.6. Model for the involvement of the Fis1/Bap31/procaspase-8 platform in Bax/Bak-
mediated permeabilization of the mitochondrial outer membrane. Additional opportunities for 
regulation involve pro-survival members of the Bcl-2 family operating at the ER, as well as 
other targets of p20Bap31 that might influence the ER membrane protein trafficking 
machinery. Figure adapted from Wang et al., 2011. 
 
Moreover, BAP31 expression has been shown to be connected to the various cancer types. 
However, this data remains controversial. Namely, Ma et al. have shown that low expression 
of BAP31 is associated with unfavorable prognosis in human colorectal cancer, when Seo et 
al. describe that enhanced expression of cell-surface B-cell receptor-associated protein 31 
contributes to poor survival of non-small cell lung carcinoma cells. Xu et al., investigating 
colorectal cancer, could show that suppression of BAP31 via MiR-451a leads to decrease in 
the proliferation and increase of apoptosis via ER-stress induction. The same was true for Chen 
et al., who focused on gastric cancer. These data show, that function of BAP31 could be 
different in various cancer types and also stress out the idea to deepen the knowledge 
concerning the function of BAP31 in cancer. 
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3. MATERIALS AND METHODS 
3.1 MATERIALS 
3.1.1 Cells 
Cell line Supplier 
CCRF-CEM  M. Kavallaris, Sydney, Australia 
HL-60  ATCC, Manassas, VA, USA 
MCF10a ATCC, Manassas, VA, USA 
MDA-MB-231 Cell line Services (CLS), Eppelheim, Germany 
SKBR3 Cell line Services (CLS), Eppelheim, Germany 
Table 3.1. List of used cell lines. 
Patient Derived Xenograft (PDX) cells were kindly provided by PhD Binje Vick, group of Prof. 
Dr. med. Jeremias (Helmholtz Center Munich, Germany) either from murine bone marrow or 
spleen. Peripheral blood mononuclear cells (PBMCs) have been freshly obtained from the 
blood of healthy volunteers as described in section 3.2.3. 
RIL175 were kindly provided by Prof. Dr. med. Simon Rothenfußer from the Center of 
Integrated Protein Science Munich and Division of Clinical Pharmacology, Department of 
Internal Medicine IV, Hospital of the Ludwig Maximilian University of Munich. 
3.1.2 Compounds 
Substance Solvent Storage (ºC) Supplier 
Brefeldin A DMSO -20ºC Sigma-Aldrich, St Louis, MO, USA 
Cerulenin Ethanol -20ºC Sigma-Aldrich, St Louis, MO, USA 
CP-640,186 Ethanol -20ºC Sigma-Aldrich, St Louis, MO, USA 
Daunorubicin DMSO -20ºC Sigma-Aldrich, St Louis, MO, USA 
Etoposide DMSO -20ºC Sigma-Aldrich, St Louis, MO, USA 
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PS89 DMSO -20ºC University of Saarland, Saarbrücken, Germany 
Soraphen A Ethanol -20ºC University of Saarland, Saarbrücken, Germany 
TOFA DMSO -20ºC Sigma-Aldrich, St Louis, MO, USA 
UCM05 Ethanol -20ºC Sigma-Aldrich, St Louis, MO, USA 
Vincristine DMSO -20ºC Sigma-Aldrich, St Louis, MO, USA 
Table 3.2. List of used compounds. 
3.1.3 Chemicals and Reagents  
Reagent Supplier 
2,2,2 - Trichloroethanol (TCE)  Sigma Aldrich, St Louis, MO, USA 
Adenine Sigma Aldrich, Taufkirchen, Germany 
Ammonium persulfate (APS)  Sigma Aldrich, St Louis, MO, USA 
Aureobasidin A Takara Bio USA, Inc., Mountain View, CA, 
USA 
BamHI New England BioLabs, Ipswich, MA, USA 
Blasticidin Thermo Fisher, Waltham, MA, USA 
Bovine Serum Albumine (BSA) Sigma Aldrich, Taufkirchen, Germany 
Cal-520 AM AAT Bioquest, Sunnyvale, CA, USA 
Calcium chloride Sigma Aldrich, Taufkirchen, Germany 
Carboxy-H2DCFDA Thermo Fisher, Waltham, MA, USA 
Cell-Titer Blue (CTB) Promega, Madison, WI, USA 
Cholera toxin from Vibrio cholerae Sigma Aldrich, Taufkirchen, Germany 
Complete® mini EDTA free Sigma Aldrich, Taufkirchen, Germany 
Coumaric acid  Fluka, Buchs, Switzerland 
Crystal Violet Carl Roth, Karlsruhe, Germany 
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D-glucose Merck, Darmstadt, Germany 
DharmaFECT transfection reagent GE Dharmacon, Lafayette, CO, USA 
Dimethyl sulfoxide (DMSO) AppliChem, Darmstadt, Germany 
Disodium hydrogen phosphate Grüssing GmbH, Filsum, Germany 
Dithiothreitol (DTT) Sigma Aldrich, Taufkirchen, Germany 
Dulbecco’s modified Eagle’s medium 
(DMEM) 
PAN Biotech, Aidenbach, Germany 
Dulbecco's Modified Eagle 
Medium/Nutrient Mixture F-12 
(DMEM/F12) 
PAN Biotech, Aidenbach, Germany 
EcoRI New England BioLabs, Ipswich, MA, USA 
EGF tetramethylrhodamine conjugate Life Technologies, Carlsbad, CA, USA 
Epidermal Growth Factor (EGF) PeproTech Inc., Rocky Hill, NJ, USA 
Ethylenediaminetetraacetic acid (EDTA) Carl Roth, Karlsruhe, Germany 
Fetal calf serum (FCS) PAN Biotech, Aidenbach, Germany 
Ficoll-Paque PLUS GE Healthcare, Chicago, IL, USA 
FluorSaveTM Reagent mounting medium Merck, Darmstadt, Germany 
Formaldehyde 16%, ultrapure Polysciences, Warrington, PA, USA 
Glycerol Sigma Aldrich, Taufkirchen, Germany 
Glycine ORG Laborchemie, Bunde, Germany 
HEPES Sigma Aldrich, Taufkirchen, Germany 
Hoechst 33342 Sigma Aldrich, St Louis, MO, USA 
Horse serum Invitrogen, Karlsruhe, Germany 
Human Methylcellulose Complete Media R&D Systems, Inc., Minneapolis, MN, USA 
Hydrocortisone  Sigma Aldrich, Taufkirchen, Germany 
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Hydrogen Peroxide Sigma Aldrich, Taufkirchen, Germany 
Insulin from bovine pancreas Sigma Aldrich, Taufkirchen, Germany 
Leucine Sigma Aldrich, Taufkirchen, Germany 
Lipofectamine 3000 Thermo Fisher, Waltham, MA, USA 
L-Tryptophan Sigma Aldrich, Taufkirchen, Germany 
Luminol AppliChem, Darmstadt, Germany 
L-α-Phosphatidylinositol ammonium salt 
solution from bovine liver – PI mix 
Sigma Aldrich, Taufkirchen, Germany 
Magnesium chloride hexahydrate Grüssing GmbH, Filsum, Germany 
Magnesium sulfate heptahydrate Grüssing GmbH, Filsum, Germany 
Matchmaker Gold Yeast Two-Hybrid 
System 
Takara Bio USA, Inc., Mountain View, CA, 
USA 
Methanol Sigma Aldrich, Taufkirchen, Germany 
Monopotassium phosphate (KH2PO4) Sigma Aldrich, Taufkirchen, Germany 
N,N,N′,N′-Tetrametyloetylenodiamina 
(TEMED) 
VWR, Radnor, PA, USA 
Nonfat powdered milk (Blotto) Carl Roth, Karlsruhe, Germany 
ON-TARGETplus siRNA against:  
ACC1, BAP31 and TRA2B 
GE Dharmacon, Lafayette, CO, USA 
Opti-MEMTM Thermo Fisher, Waltham, MA, USA 
Page Ruler TM Prestained Protein Ladder Thermo Fisher, Waltham, MA, USA 
Penicillin/Streptomycin 100x PAA Laboratories, Pasching, Austria 
Phenylmethylsulfonyl fluoride (PMSF) Sigma Aldrich, Taufkirchen, Germany 
Pierce™ BCA Protein Assay Kit 
Thermo Fischer Scientific, Waltham, MA, 
USA 
19 
 
Polyacrylamide (Rotiphorese® Gel A 30%) Carl Roth, Karlsruhe, Germany 
Potassium chloride AppliChem GmbH, Darmstadt, Germany 
Propidium iodide Sigma Aldrich, Taufkirchen, Germany 
Puromycin Thermo Fisher, Waltham, MA, USA 
Pyronin Y Sigma Aldrich, Taufkirchen, Germany 
Pyruvate Merck, Darmstadt, Germany 
Roswell Park Memorial Institute (RPMI) 
1640 Medium 
PAN Biotech, Aidenbach, Germany 
siRNA buffer (5x) GE Dharmacon, Lafayette, CO, USA 
Sodium bicarbonate Grüssing GmbH, Filsum, Germany 
Sodium chloride (NaCl) Sigma Aldrich, Taufkirchen, Germany 
Sodium citrate Carl Roth, Karlsruhe, Germany 
Sodium dodecyl sulfate (SDS) AppliChem, Darmstadt, Germany 
T7 Endonuclease I New England BioLabs, Ipswich, MA, USA 
Transferrin from human serum 
tetramethylrhodamine conjugate 
Invitrogen, Karlsruhe, Germany 
Tris Sigma Aldrich, Taufkirchen, Germany 
Tris-HCl Sigma Aldrich, Taufkirchen, Germany 
Triton X-100 Merck, Darmstadt, Germany 
Trypsin PAN Biotech, Aidenbach, Germany 
Tween® 20 BDH/Prolabo®, Ismaning, Germany 
X-α-Gal Takara Bio USA, Inc., Mountain View, CA, 
USA 
20 
 
Yeast Synthetic Drop-out Medium 
Supplements without histidine, leucine, 
tryptophan and uracil (QDO) 
Sigma Aldrich, Taufkirchen, Germany 
Yeast Synthetic Drop-out Medium 
Supplements without Leucine and 
Tryptophan (DDO) 
Sigma Aldrich, Taufkirchen, Germany 
Table 3.3. List of chemicals, reagents, inhibitors and kits used during experiments. 
 
All commonly used acids, bases, buffer salts and organic solvents were either purchased from 
Merck (Darmstadt, Germany) or Sigma-Aldrich (St Louis, MO, USA). 
 
3.1.4 Primary antibodies 
Antibody Product No. Origin Supplier 
ACC1  #4190 Rabbit Cell Signaling, Danvers, MA, USA 
BAP31 (B-10) sc-365347 Mouse Santa Cruz, Dallas, TX, USA 
BCAP31 HPA003906 Rabbit Sigma Aldrich, St Louis, MO, USA 
BiP 610978 Mouse BD, Franklin Lakes, NJ, USA 
Caspase-3 C8487 Rabbit Sigma Aldrich, St Louis, MO, USA 
Caspase-8 #9746 Mouse Cell Signaling, Danvers, MA, USA 
CD34 555821 Mouse BD, Franklin Lakes, NJ, USA 
Cytochrome c #4272 Rabbit Cell Signaling, Danvers, MA, USA 
EGFR  #2239 Mouse Cell Signaling, Danvers, MA, USA 
EGFR pTyr1068  #2234 Rabbit Cell Signaling, Danvers, MA, USA 
HER2  #2156 Rabbit Cell Signaling, Danvers, MA, USA 
HER2 pTyr1221/1222  #2243 Rabbit Cell Signaling, Danvers, MA, USA 
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Histone 3 ab1791 Rabbit Abcam, Berlin, Germany 
LC3 I/II #4108 Rabbit Cell Signaling, Danvers, MA, USA 
NF-kB p65 sc-372 Rabbit Santa Cruz, Dallas, TX, USA 
PARP #9542 Rabbit Cell Signaling, Danvers, MA, USA 
PRMT2 AV40196 Rabbit Sigma Aldrich, St Louis, MO, USA 
SQSTM1/p62 #5114 Rabbit Cell Signaling, Danvers, MA, USA 
TRA2B ab31353 Rabbit Abcam, Berlin, Germany 
VDAC #4866 Rabbit Cell Signaling, Danvers, MA, USA 
Table 3.4. List of primary antibodies used in experiments. 
 
3.1.5 Secondary antibodies 
Antibody Product No. Origin Supplier 
Alexa Fluor 488-conjugated 
mAb18 
A-11008 Goat  Invitrogen, Karlsruhe, Germany 
Alexa Fluor 546-conjugated 
mAb18 
A-11003 Goat  Invitrogen, Karlsruhe, Germany 
Alexa Fluor 633-conjugated 
mAb18 
A - 21050 Goat  Invitrogen, Karlsruhe, Germany 
HRP, Anti-Mouse IgG1 ab97240 Goat Abcam, Berlin, Germany 
HRP, Anti-Rabbit 111-035-144 Goat Dianova, Hamburg, Germany 
HRP, Anti-Rabbit IgG 172-1019 Goat Bio-Rad, Hercules, CA, USA 
Table 3.5. List of secondary antibodies used in experiments. 
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3.1.6 Technical equipment 
Device Function Manufacturer 
Abbocath-T 14 G, 2,2 x 51 
mm 
Cannula ICU Medical Germany GmbH, 
Lüdenscheid, Germany 
Amersham NC/PVDF 
(0,2μM, 0,45μM) 
Blotting membrane 
GE Healthcare, Chicago, IL, USA 
BD Discardit 5ml Eccentric 
Tip Syringe 
Syringe BD Biosciences, Heilderberg, 
Germany 
BD FACS CantoTM II Flow cytometer BD Biosciences, Heilderberg, 
Germany 
Canon EOS 450C Camera Canon, Tokyo, Japan 
Cell culture flasks, tubes and 
plates 
Disposable cell culture 
material 
Nunc, Thermo Fisher, Waltham, 
MA, USA 
ChemidocTM Touch Imaging 
System 
Immunoblot Imaging 
Bio-Rad, Hercules, CA, USA 
Consort power supply E835 Electrophoresis Sigma Aldrich, St Louis, MO, 
USA 
HBT 130-2 
 
Thermoblock 
 
Haep Labor Consult, Bovenden, 
Germany 
HeraCell  Incubator Heraeus, Hanau, Germany 
ibiTreat μ-slide Microscopy 8-well slide Ibidi, Planegg, Germany 
Mikro 22R Microcentrifuge Hettich, Tuttlingen, Germany 
Mini Protean 3 Electrophoretic transfer Bio-Rad, Hercules, CA, USA 
NucleofectorTM II Device Transfection through 
electroporation 
Lonza, Basel, Switzerland 
Olympus CK30 Inverted microscope Olympus, Tokyo, Japan 
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Rotina 46R Centrifuge  Hettich, Tuttlingen, Germany 
SP8 LSM system Confocal microscope Leica, Wetzlar, Germany 
SpectraFluor Plus Fluorescence reader Tecan, Ma nnedorf, Switzerland 
Tecan Sunrise Absorbance reader Tecan, Ma nnedorf, Switzerland 
Thermoshake, Laboshake Thermoshaker Gerhard Analytical Systems, 
Königswinter, Germany 
Tube 4ml, 75x12mm, K3E 
Blood collection SARSTEDT AG & Co. KG, 
Nümbrecht, Germany 
Vi-CellTM XR Cell viability analyzer Beckman Coulter, Brea, CA, USA 
Zeiss LSM 510  Confocal microscope Zeiss, Oberkochen, Germany 
Table 3.6. List of technical equipment necessary for cell culture and analytics. 
 
3.1.7 Software 
Software name and version  Supplier 
BioRender BioRender, Toronto, Ontario, USA 
BLAST NCBI, U.S. National Library of Medicine, 
Bethesda, MD, USA 
DNAMAN Lynnon LLC., San Ramon, CA, USA 
FlowJo v7.6.5 Tree Star, Ashland, OR, USA 
GraphPad Prism 7/8 GraphPad Software, San Diego, CA, USA 
Image Lab v5.2 Bio-Rad, Hercules, CA, USA 
ImageJ National Institutes of Health, LOCI, 
University of Wisconsin, USA 
Leica LAS X  Leica, Wetzlar, Germany 
Microsoft Office 2016 Microsoft, Redmont, WA, USA 
Table 3.7. Software used for the evaluation and analysis of the data. 
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3.2 CELL CULTURE 
3.2.1 Maintenance of cell lines 
SKBR3, MDA-MB-231 as well as RIL-175 cancer cell lines were cultivated in DMEM culture 
medium supplemented with 10% fetal calf serum (FCS) and 1% Penicillin/Streptomycin (P/S). 
MCF10A mammary epithelial cells were cultivated in DMEM/F12 Mix 1:1 supplemented with 
5% horse serum, 20 µg/l EGF, 10 mg/l insulin, 0,5 mg/l hydrocortisone, 0,1 mg/l cholera toxin 
and 1% P/S. HL-60 and CCRF-CEM cell lines were cultivated in RPMI 1640 medium with 2 mM 
glutamine supplemented with 10% FCS and 1% of P/S. All the cell lines were kept in a humidified 
incubator at 37°C under a 5% CO2 atmosphere. 
Cells were passaged twice a week before they reached 90% confluence. To detach them from the 
culture dish, after washing flask twice with PBS (Table 3.8.), 1ml of Trypsin/EDTA (T/E) solution 
(Table 3.8.) was added. Cells were incubated together with T/E at 37ºC until all of them lost their 
adhesion to the bottom of the culture dish. The trypsinization process was stopped with 10ml of 
complete culture medium. Cell density was determined using Vi-CellTM XR device. One million 
of either SKBR3 or MDA-MB-231, two million of MCF10A or 0,5 million of RIL-175 were 
seeded back in the culture flask for further cultivation. 
Suspension cell lines were split by using one million of cells per 10 ml of fresh medium. 
 
 
 
 
 
 
Table 3.8. Buffers and solutions commonly used in cell culture. 
 
 
Phosphate-buffered saline (PBS), pH 7,4 Trypsin/EDTA 
NaCl                                       123,3 mM Trypsin              0,05% 
Na2HPO4                                10,4 mM EDTA                0,02% 
KH2PO4                                  3,2 mM PBS 
H2O 
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3.2.2 Freezing and thawing process 
To store the cells for a long term, they were frozen in liquid nitrogen. For the cryopreservation 
purpose, the cultivation medium was supplemented with 20% FCS, 1% P/S and 10% DMSO. One 
milliliter of cell suspension in concentration of 1·106/ml was transferred into each cryovial. Cells 
were frozen at -80ºC for 24 hours and, subsequently, transferred to the tanks with liquid nitrogen. 
To thaw the cell line, cells were taken from the storage tank and quickly thawed in a water bath at 
37ºC. Once the suspension of cells became liquid, it was transferred to the falcon tube containing 
10 ml of fresh, complete medium. Cells were centrifuged for 5 minutes at 1000 rpm. Supernatant 
was discarded and cells were re-suspended in 5 ml of complete culture medium. Next, they were 
transferred into a T25 cell culture flask.  
 
3.2.3 Isolation of Peripheral Blood Mononuclear Cells (PBMCs) 
Blood samples were collected from healthy volunteers to EDTA-coated vials. Subsequently, blood 
was diluted 1:1 with PBS and layered on top of Ficoll-Paque PLUS density gradient media in 50ml 
plastic tubes. Next, tubes were centrifuged for 40 minutes at 1490 rpm. Both parameters – accel 
and decel – were set to 1, to avoid disruption of layers through rapid start or stop of the centrifuge.  
The layer of PBMCs (Figure 3.1.) was collected using a big needle and a syringe and washed once 
with PBS. Cells were re-suspended in RPMI 1640 medium supplemented with 1 mM pyruvate, 
20% FCS and 1% P/S, seeded in appropriate plates and stimulated with compounds of choice. 
  
Figure 3.1. Layers obtained after gradient centrifugation using a Ficoll-Paque PLUS reagent. 
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3.2.4 Generation and isolation of patient derived xenograft cells (PDX) 
Cultivation of Patient Derived Xenograft (PDX) cells in vivo was described by Terziyska N. et al., 
2012 and Vick B. et al., 2015. For the purpose of experiments, cells were freshly separated from 
either spleen or bone marrow of NOD scid gamma (NSG) mice. Subsequently, they were 
cultivated in RPMI 1640 medium supplemented with 4µg/l Na Selen, 6mg/l Insulin, 
3mg/lTransferin, 1 mM Natrium Pyruvat and 50 µM a-Thioglycerol (a-TG) in the presence of 
compounds or with the mock. 
 
3.2.5 Stimulation with compounds 
Cells were seeded one day before stimulation and left overnight to appropriately attach to the 
experimental dish. Compounds were dissolved in culture medium. Controls were treated with the 
highest volume of solvent used for stimulation during the experiment. DMSO, as a solvent, did 
not exceed 0,5% of experimental volume of medium. A list of compounds is provided in Table 
3.2. 
 
3.3 PROLIFERATION AND ATTACHMENT ASSAYS 
3.3.1 Cell-Titer Blue® viability assay 
Cell-Titer-Blue® (CTB) viability assay (Promega, Madison, WI, USA) was used to determine 
proliferation rate of experimental cells. This assay relays on the ability of living cells to metabolize 
a redox dye – Resazurin – into a fluorescent product – Resorufin. As dying cells are losing their 
metabolic capability, they do not generate any fluorescent singal.  
To determine the proliferation capacity, cells were seeded in 96-well plates in a number of 1000 
cells/well. On the next day, cells were treated with compounds of our choice (Em experimental) 
or mock (Em control), and further cultivated in complete medium in a total amount of 200µl. After 
72 or 96 hours of proliferation, 40µl of CTB reagent was added to each well. Cells were incubated 
for 2 hours at 37ºC. The fluorescent signal was recorded at 595nm, with an excitation at 550 nm, 
using a Tecan SpectraFluor Plus microplate reader. The signal assessed at day 0 served as a 
reference (Em reference). The proliferation of cells was calculated as follows: 
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𝐸𝑚 𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 − 𝐸𝑚 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒
𝐸𝑚 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝐸𝑚 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒
× 100% = 𝑝𝑟𝑜𝑙𝑖𝑓𝑒𝑟𝑎𝑡𝑖𝑜𝑛 
 
3.3.2 ViCell – counting of the cell number 
Cells were seeded in 24-well plates in the number of 0,5·105 cells/well in 400 µl of culture medium 
in triplicates. They were cultivated for 72 hours and, subsequently, trypsinized, diluted in 2ml of 
culture medium and counted using ViCell device. The data has been normalized to 100% for the 
wild type control. 
 
3.3.3 xCELLigence – the real-time analysis of the cellular growth and attachment 
Cells have been seeded in the number of 4·103 cells/well in the special plate. Right after the 
seeding, the plate was installed in the xCELLigence device and the real-time measurement was 
conducted for the next 72 hours. Subsequently, the data were analyzed using the RTCA 2.0 
software, which allows the calculation of the doubling time for each sample.  
Out of this data, we were able to compare also the attachment ability of the cells. For this purpose, 
we analyzed a change in the cell index just for the first 120 minutes.  
 
3.3.4 Attachment analysis – crystal violet staining 
To verify the attachment capability of the cells, they were seeded in the number of 0,5·106 
cells/well in 6-well plates and left for 30 minutes, 37ºC to attach to the bottom of the well. Next, 
not attached cells were washed out with PBS. Remaining cells were stained using 500 µl of crystal 
violet solution for 5 minutes with shaking. Next, the crystal violet was washed out and the number 
of cells attached to the bottom was counted. 
 
3.3.5 Colony formation assay 
Leukemia HL-60 cells pre-treated for 24h with either single treatment with PS89 25µM, 
Mercaptopurine 100µM, or combination of those compounds were seeded in the amount of 1·104 
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/well in 1ml of Human Methylcellulose Complete Media in triplicates into 12-well plate. Single 
cells were distributed equally over the well and incubated for 7 days at 37°C to check their ability 
to form the colonies out of the single cell. After 7 days, the pictures were captured, and the number 
of colonies was counted using Image J software. 
 
3.4 IMMUNOBLOTTING 
3.4.1 Preparation of samples 
Cells, after an appropriate treatment, were washed twice with PBS and lysed using Triton X-100 
lysis buffer (Table 3.9.), 200µl/well in 6-well plate. Immediately, plates were frozen at -20ºC for 
at least 1 hour to improve lysis of all the cellular membranes. Subsequently, samples were thawed 
on ice for 30 minutes. Next, they were scratched from the plates and transferred to the 1,5 ml 
plastic tubes. Samples were centrifuged for 10 minutes at 14 000 rpm. Supernatant was used for 
further determination of protein concentration. 
Triton X-100 lysis buffer (pH 8,0) 
NaCl                                   150mM 
Tris-HCl                             50mM 
Triton X-100                      1% 
Complete 25x                     4% 
Table 3.9. Tritron X-100 lysis buffer used to prepare samples for immunoblotting. 
 
3.4.2 Preparation of samples for the cytosol/mitochondrial fractionation 
Cells were seeded in 10 cm petri dishes in a number of 1 million in 10 ml of medium. To isolate 
the fractions of cytoplasm and mitochondria, cells after the required stimulation were lysed with 
Digitonin lysis buffer (Table 3.10) for 20 minutes on ice. Next, cells were collected to the 1,5ml 
plastic tubes and centrifuged for 10 minutes at 13 000 rpm. The supernatant was collected to the 
fresh tube as the cytosolic fraction. The pellet was subjected to the lysis with Triton X-100 lysis 
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buffer (Table 3.9) for 30 minutes on ice. Subsequently, the mixture was centrifuged for 10 minutes 
at 14 000 rpm and the supernatant was collected as the mitochondrial fraction. 
Digitonin Lysis buffer (pH 7,2) 
Hepes 7,2 pH                        10mM    
Na2EGTA                           0,2 mM 
Succinate                               5 mM 
Sucrose                             200 mM 
BSA                            0,15% (w/v) 
Mannitol                             210 mM 
Digitonin                           80 μg/ml 
H2O 
Table 3.10. Digitonin lysis buffer used to prepare samples for immunoblotting. 
 
3.4.3 Preparation of samples for the cytosol/nuclear fractionation. 
Cells were seeded in 10 cm petri dishes in a number of 1 million in 10 ml of medium. To isolate 
the fractions of cytoplasm and nucleus, cells were detached using T/E, centrifuged for 5 minutes 
at 1000 rpm and the medium was discarded. Cells were washed with PBS and lysed with 5 pellet 
volumes of Cytoplasmic Extract (CE) Buffer (Table 3.11) for 3 minutes on ice. Next, cells were 
centrifuged for 10 minutes at 13 000 rpm. The collected supernatant was transferred to the fresh 
tube as the cytosolic fraction. The pellet was subjected to the lysis with 2 pellet volumes of Nuclear 
Extract (NE) buffer and 30 µl of 5 M NaCl (Table 3.11) for 20 minutes on ice. Subsequently, the 
mixture was centrifuged for 10 minutes at 14 000 rpm and the supernatant was collected as the 
nuclear fraction. Both supernatants were centrifuged once again to discard the remaining pollution. 
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Cytoplasmic Extract buffer (pH 7,6) 
Hepes pH 7,6                                 10 mM    
KCl                                                 60 mM 
EDTA                                             1 mM 
NP40                                     0,075% (v/v) 
DTT                                                1 mM 
PMSF                                             1 mM 
Complete protease inhibitor 
H2O 
Table 3.11. Cytoplasmic Extract and Nuclear extract buffers used to prepare samples for 
immunoblotting. 
 
3.4.4 Determination of protein concentration 
 Pierce™ BCA Protein Assay Kit relays on the reduction of Cu2+ to Cu+. In the first step copper is 
chelated by a protein. This reaction leads to the formation of light blue complex. In the second step 
of the reaction, bicinchoninic acid (BCA) reacts with the reduced (cuprous) cation that was formed 
in step one. The intense purple-colored reaction product results from the chelation of two 
molecules of BCA with one cuprous ion. The absorbance is measured at 550 nm wave length.  
To ensure that the same amount of the protein is loaded, each sample was diluted 1:5 with water 
and triplicates of the dilution, 10 µl each, were transferred onto 96-well plate. Bovine Serum 
Albumin (BSA) standards were used to create a standard curve. To each well 190 µl of Pierce™ 
BCA Protein Assay Kit solution was added, and the plate was incubated for 40 minutes, room 
temperature, shaking in dark. Subsequently, absorbance was measured with Tecan Sunrise reader 
and the protein concentration was determined by linear regression using GraphPad Prism 7/8 
software. Samples for western blot were prepared using 40 µg of protein mixed with SDS sample 
buffer (Table 3.12.). Samples were boiled for 5 minutes at 95ºC. 
 
Nuclear Extract buffer (pH 8,0) 
Tris-HCl pH 8,0                        20 mM    
NaCl                                           420 mM 
EDTA                                        200 µM 
MgCl2                                         1,5 mM 
PMSF                                            1 mM 
Glycerol                                   25% (v/v) 
Complete protease inhibitor 
H2O 
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5x SDS sample buffer 
Tris-HCl (pH 6,8)           3.125 M 
Glycerol                          50 % 
SDS                                 5 % 
DTT                                 2 % 
Pyronin Y                        0,025% 
H2O 
Table 3.12. Sample buffers used for western blot. 
 
3.4.5 Sodium dodecyl sulfate – polyacrylamide gel electrophoresis (SDS-PAGE) 
To separate the proteins according to their size, polyacrylamide gels were used (Table 3.13.).  The 
density of the gel was adjusted to the protein size, mostly 12%. The chamber of a Mini Protean 3 
system from Bio-Rad was filled with electrophoresis buffer (Table 3.13.) and prepared samples 
were loaded. A Page Ruler Pre-stained protein ladder was used as a reference for a protein size. 
Electrophoresis was performed for 20 min at 100V and 40 min at 200 V. Subsequently, gels were 
imaged using ChemiDocTM Touch Imaging system for further evaluation of samples loading. The 
“stain free” setting allows to detect trichloroethanol (TCE), which is added to the separation gel. 
 
1x SDS sample buffer 
5x SDS sample buffer          20% 
H2O 
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Table 3.13. Recipes for electrophoresis and gels used for western blot. 
 
3.4.6 Blotting process 
To transfer proteins onto the membrane of choice (depending on the protein size either PVDF or 
Nitrocellulose), in order to make them accessible for the detection, a “sandwich” was carefully 
composed of blotting paper, gel, membrane and sponge filters. This complex composition was 
transferred into the blotting tank supplemented with ice pack and 1x tank buffer (Table 3.14.). The 
blotting process was performed for 1,5 hours at 100 V at 4ºC. To cool the tank buffer more 
efficiently a magnetic stirrer was used.  
 
 
 
 
 
Table 3.14. Buffer used for blotting process. 
Stacking gel 
Rotiphorese Gel 30    17 % 
Tris-HCl (pH 6,8)  125 mM 
SDS                            0,1 % 
TEMED                      0,2 % 
APS                            0,1 % 
H2O 
Separation gel 12% 
Rotiphorese Gel 30     40 % 
Tris-HCl (pH 8,8)  375 mM 
SDS                            0,1 % 
TEMED                      0,1 % 
APS                          0,05 % 
TCE                            0,5 % 
H2O 
Electrophoresis buffer 
Tris                      4,9 mM 
Glycine                 38 mM 
SDS                       0,1 % 
H2O 
   Tank buffer 5x 
Tris-Base       240 mM 
Glycine          195 mM 
H2O 
Tank buffer 1x 
Tank buffer 5x 20 % 
Methanol 20 % 
H2O 
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3.4.7 Protein detection 
To avoid unspecific binding of antibodies, the membrane was blocked using 5% Blotto solution 
(Table 3.15.) for at least 1 hour. Next, primary antibody diluted 1:1000 in 5% BSA was applied 
and membrane was incubated overnight at 4ºC. Subsequently, the membrane was washed 3 times 
for 5 minutes with the PBS-T buffer (Table 3.15.). Following, the membrane was incubated with 
a secondary antibody diluted 1:1000 in 1% Blotto solution for next 2 hours, room temperature. 
After that, membrane was washed once again as described above.  
To detect a signal from enhanced chemiluminescence (ECL), an ECL solution (Table 3.15.) was 
applied for 1 minute. In this type of detection, horseradish peroxidase (HRP) conjugated to the 
secondary antibody oxidizes luminol. Chemiluminescent signal was visualized using ChemiDocTM 
Touch Imaging system. Evaluation of Western Blots was performed using Image LabTM software. 
 
 
  
 
Table 3.15. Buffers used for the membrane development. 
 
3.5 FLOW CYTOMETRY 
3.5.1 Analysis of apoptosis 
Loss of the nuclear DNA due to the DNA fragmentation is characteristic for the apoptosis process. 
The usage of the fluorochrome like propidium iodide (PI), which binds to the DNA, enables a 
rapid and precise evaluation of the cellular DNA content. Using flow cytometry enables 
PBS-T (pH 7,6) 
NaCl                  123,3 mM 
Na2HPO4             10,4 mM 
KH2PO4                 3,2 mM 
Tween20                  0,1 % 
H2O 
ECL buffer 
Tris (pH 8,5) 100 mM 
Luminol 2,5 mM 
Coumaric acid 1mM 
H2O2 17 µM 
H2O 
Blotto 5% 
Milk Powder                    5% 
PBS-T 
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identification of the population of the cells which are hypodiploid (Nicoletti et al., 1991). 
Therefore, propidium iodide staining can be applied to analyze a sub-G1 population of the cells, 
which are containing less DNA in comparison to the cells in the normal state, what indicates that 
they are apoptotic.  
To analyze the apoptosis rate, cells were seeded and treated with compounds as depicted. Next, 
the cells were harvested and put to the plastic FACS tubes (detached with T/E, if applicable) and 
centrifuged 5 minutes, 1000 rpm, 4ºC. The supernatant was discarded. Cells were washed with 
1ml of PBS and centrifuged as described above. PBS was discarded and 200µl of HFS solution 
(Table 3.16.) was added to each tube. FACS measurement was performed not earlier than 30 
minutes after staining. 
For the analysis of apoptosis Flow-Jo 7.6 software was used. It was assessed as a percent of sub-
G1 population out of all events. To analyze the cell cycle frequency, the PI stained cells were 
recorded on the linear x-axis and analyzed applying Watson Pragmatic univariate model. 
Hypotonic Fluorochrome Solution (HFS) 
Propidium iodide 50 μg/ml 
Sodium citrate 0.1% (w/v) 
Triton X-100 0.1% (v/v) 
PBS 
Table 3.16. Hypotonic Fluorochrome Solution (HFS). 
 
3.5.2 Measurement of cytosolic calcium level 
Cal-520 AM dye can easily cross the cellular membrane. Once it is inside a living cell, its lipophilic 
blocking groups are cleaved by esterases. This leads to a change of the molecular charge from 
positive to negative, what prevents the dye to cross the cellular membrane back. When the 
imprisoned dye binds to the calcium ions, its fluorescence is greatly enhanced. 
To measure the level of calcium ions in the cytoplasm, the cells were loaded with 1µM solution of 
Cal-520 AM dye in Hanks and Hepes Buffer (HHBS, Table 3.17.) for 90 minutes at 37ºC and 30 
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minutes at room temperature. To load the cells with the dye, they were harvested to plastic FACS 
tubes, centrifuged (1000 rpm, RT, 5min) and the supernatant was discarded. The Cal-520 AM dye 
solution was applied. Next, the cells were washed with HHBS and re-suspended in 200µl of 
propidium iodide solution in HBSS. The FACS measurement was performed immediately after 
staining.  
Propidium iodide staining was used to distinguish between dead and living cells. Compensation 
calculation was applied to define each dye. Using Flow Jo 7.6 software, PI positive cells were 
excluded and the living cells were evaluated for Cal-520 AM fluorescent signal intensity using the 
FACSCanto II device at Ex 488 nm and Em 530/30 nm. 
HHBS (pH 7,2) 
CaCl2                            1,26 mM  KCl                           5,33 mM MgSO4 x 7 H2O      0,41 mM 
D-glucose                     5,56 mM  KH2PO4                    0,44 mM Na2HPO4                  0,34 mM 
Hepes                               20 mM  MgCl2 x 6 H2O       0,49 mM NaCl                       137,9 mM 
NaHCO3                                 4,17 mM H2O  
Table 3.17. Hanks and Hepes Buffer. 
 
3.5.3 Measurement of Reactive Oxygen Species (ROS) level 
Carboxy-H2DCFDA (6-carboxy-2',7'-dichlorodihydrofluorescein diacetate) is an acetated form of 
fluorescein, which is used to measure cellular levels of reactive oxygen species. Carboxy-
H2DCFDA is a non-fluorescent dye and the esterase cleavage of its lipophilic blocking groups 
yields a charged form of the dye that is much better retained by cells than is the parent compound.  
Once the carboxy-H2DCFDA diffuses into the cell, esterases cleave the dye what makes it 
impossible to escape from the cell. Next, the Reactive Oxygen Species (ROS) - present in the 
cytoplasm when the apoptosis occurs, can oxidize the dye, what results in the fluorescence. 
Oxidation of these probes can be detected by monitoring the increase in fluorescence with a flow 
cytometer, fluorometer, microplate reader, or fluorescence microscope, using excitation sources 
and filters appropriate for fluorescein (FITC). 
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Cells harvested into plastic FACS tubes were centrifuged and the supernatant was discarded. The 
cells were washed with PBS and loaded with dye (20 μM in PBS) for 45 min at 37°C in the dark. 
After the incubation, excess of the dye was removed. Cells were washed once again and re-
suspended in 200µl of PBS. FACS measurement was conducted immediately after the staining, 
using a FACS Canto II device at Ex 488 nm and Em 530/30 nm.  
Propidium iodide staining was used as a counterstaining as described in the section 3.5.2. 
 
3.5.4 Identification of apoptosis in the CD34+ cells 
To identify CD34+ cells, PBMCs were isolated as described in the section 3.2.3. Appropriate 
treatment was applied. Next, the cells were centrifuged for 5 minutes at 1000 rpm. Culture medium 
was discarded, and cells were washed with PBS. For the immuno-staining cells were re-suspended 
in PBS containing FITC-conjugated antibody directed against CD34 antigen (BD Pharmingen™, 
Heidelberg, Germany) and incubated for 1 hour, shaking in the dark, RT. After the incubation, 
cells were washed and re-suspended in PBS-Propidium iodide mixture. 
FACS Canto II flow cytometer was used for the measurement. The gating was set according to the 
Fukuda et al. (1998). FITC-positive population in a number of 25 000 events was used as a 
stopping gate. PI-positive values were used to calculate the specific apoptosis rate as depicted here:  
 
 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑎𝑝𝑜𝑝𝑡𝑜𝑠𝑖𝑠 [%] =
𝐴𝑝𝑜𝑝𝑡𝑜𝑠𝑖𝑠 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠[%]− 𝐴𝑝𝑜𝑝𝑡𝑜𝑠𝑖𝑠 𝑖𝑛 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 [%]
100%−𝐴𝑝𝑜𝑝𝑡𝑜𝑠𝑖𝑠 𝑖𝑛 𝑐𝑜𝑛𝑡𝑟𝑜𝑙[%]
× 100 
 
3.6 TRANSIENT TRANSFECTION OF CELLS 
3.6.1 Transfection with siRNA 
First, the cells were seeded in the amount that gave about 80-90% of confluence on the other day. 
For the transfection purpose, culture medium was changed to one without P/S. Silencing RNA 
(siRNA) was prepared as described by a supplier (Dharmacon GE, Lafayette, CO, USA). 
DharmaFECT Transfection Reagent was used according to the manufacturer’s instruction. Briefly, 
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2,5µl of 20µM siRNA was mixed with 197,5µl of the medium without FCS and without P/S in 
tube 1, and 5µl of DharmaFECT reagent with 195µl of the same medium in tube 2. After 5 minutes 
of incubation the content of both tubes was combined into one. After additional 20 minutes of 
incubation the mixture was added to cells for at least 24 hours in the incubator. 
 
3.6.2 Transfection with plasmid 
For the transient transfection with plasmid, a Lipofectamine® 3000 kit (Thermo Fisher, Waltham, 
MA, USA) was used according to manufacturer instructions. Briefly, cells were seeded a day 
before transfection in amount that result in 80-90% of confluence on the other day. The culture 
medium was changed to 2ml of one without P/S. Plasmid DNA was diluted with Opti-MEMTM 
medium in one tube with P3000TM reagent. In another tube LipofectamineTM 3000 was diluted 
with Opti-MEMTM medium. The content of the tubes was combined, vortexed and incubated for 
10 minutes in room temperature. The mixture was added to the cells and incubated at least 24 
hours in the incubator. 
 
3.7 GENOME EDITING USING THE CRISPR-CAS9 TECHNIQUE 
3.7.1 Design of targeting components. 
To generate a knock-out of BAP31 in RIL-175 cancer cell line, we decided to use the 
CRIPSR/Cas9 technique as described before (Ran et al., 2013). To design the guide RNA (gRNA), 
the sequence of BAP31 protein was checked on the website http://www.ensembl.org. We decided 
to remove exon 3, what should result in a truncated protein, which further will be subjected to the 
nonsense mediated mRNA decay (NMD). Sequence used for the design of gRNA was depicted as 
Figure 3.2. Exon 3 sequence was shown in green, where bold part represents the coding region. 
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To design the guide RNAs we used website http://crispor.tefor.net as described before (Haeussler 
et al., 2016). Three of the most specific suggestions were picked for each: forward and revers 
gRNAs (Hsu et al., 2013) as depicted in table 3.18.  
 
Guide RNAs sequences 
Forward Reverse 
88 / fw: TGTTCCTATAGCAGTCCATA TGG  137 / rev: ATAACTAGGGTAGGGTATCT TGG  
50 / fw: CAGCATGAAACTCCTCCCGA AGG 145 / rev: GTTCTAAAATAACTAGGGTA GGG  
363 / fw: GAAAAGTAAGTTACCCTTAC TGG  42 / rev: TCATCTAAAGAGCCTTCGGG AGG   
Table 3.18. Sequences of gRNA designed for generation of BAP31 knock out cells. 
Figure 3.2. A sequence of mBCAP31 gene. Includes Exon 3 (green) and parts of introns (black). 
Sequence of mBCAP31, Exon 3: 1301 bp; 
 
1      CATGATCAGC CGAGCTTGCT GATTTTTAAC AGCATGAAAC TCCTCCCGAA GGCTCTTTAG 
61     ATGATATAGC TAAATTATTT GTTCATAGAA ATGATGGAGA GTCTAGATTC CTTTTCATAA 
121    CCTAGGGTGG TAGGAGTCTA GACCAAAAAA AAAAAAAGTA TCACATTTTA AACAAAGGGG 
181    AGCCAGGAAT AGTGGTGGCA CACTTCTTTA ATCCTGCCAT TGTGAGACAG GCAAGCGGAT 
241    CTTTGCGAGC TTGAGGCTAG CCTCATCTAC ATAGTGAGAC CCTGCCTGTC TCAAAACCAT 
301    GTTTGTAGCA GGTGTTTTAT CTACTACAAA GGGAAGTATG ATGAAAAGTA AGTTACCCTT 
361    ACTGGAAACT GCCAGGATTT TAAAGATTGA CTTTCCAGGT GTTTCTGCAT ATGCATAAAC 
421    ATCTTTTTCT AAATCCTTTT GAAGTTAATG AATAGGAAAG GCATAGCAGT AGCTGAGACT 
481    GATTTTTGTA TGGGGCCTCG TAGCCACTGC AGAAGAGCAC CAAGTTGTCC TTAAATTTTG 
541    CTTAGGGTTT GGATTGCAAA AGTTCATTTT CTTCAATATC TGTCTTCATT TCTTTCACAG 
601    ATGGCAGAAG GTTTTTAAAT CCCGGCTGGT GGAGTTGGTA GTGACCTATG GCAACACTTT 
661    CTTTGTGGTT CTCATCGTCA TCCTTGTACT GTTGGTTATT GGTGAGTGAG CTGTAGCAGG 
721    AGGTTGCTAT CTGACCAGAT CCTGTGTCAT GGCTTCTAAA GCTCTGTGCC ACATTGGAAA 
781    ATAAGCATTC TCAGAATCAA ACTCAATAAG TGCCCTTTGA TAATCTGTTA AGGAAGTGCT 
841    TGCTATTAGC AGGACCTTCA TTTCAAGATG TTCCTATAGC AGTCCATATG GACTTAAACT 
901    CAATGGCCTT TATATACTCT TATGACCACA TTTGTTACCA AGATACCCTA CCCTAGTTAT 
961    TTTAGAACTG GTACTAAGAG AAGCTAATGG TCTGTGACCC TGATTCAAAT AGTGGTGTTT 
1021   ATTAGTCATG TGGATCAGAC TTCTTTTTTA AGAAATTATT TTGTCTTTTA TTTGTCATTG 
1081   TTATTATTTT GTTTTTTTGA GACAATGTCT CTATGTGGCC CTGGATGTCA TGGCACTTGC 
1141   TCTGTAGACC AGGCTGGCCT TGAATTTATA GAGATCCATC TGCTGCTTTC TAAGTTCTGA 
1201   GATTAAAAAG GTGTGCACTG GGCTGCTTTT GTTATCTTAA AAATGTTGTT TTCTTAATCT 
      1261   TAAAAAAGAC ACCTGAGTTT GTTTGTTTGT TTGTTTGTTT G 
   
 
39 
 
3.7.2 Cloning of oligos into Cas9 plasmid  
Designed DNA oligos were cloned into eCas9_Puro2.0 Plasmid. First, all designed oligos were 
annealed using a PCR cycler for 5 minutes at 95°C and then ramping down to 25°C for another 20 
minutes (Table 3.19). 
Reagent Volume (µl) 
sgRNA fwd (100 µM) 1 
sgRNA rev (100 µM) 1 
T4 ligation buffer 10x 1 
H2O 7 
Table 3.19. PCR reaction for annealing of oligos. 
 
Subsequently, oligos were diluted 1:200 with water. Next, the restriction digestion of plasmid 
backbone was performed at 37°C for 30 minutes as depicted in Table 3.20. 
Reagent Volume (µl) 
eCas9_Puro2.0 Plasmid 150 ng x 
FD Buffer colorless 10x 1,5 
FD BbsI bzw BpiI 1 
H2O Ad 15 
Table 3.20. Digestion of plasmid backbone with restriction enzymes. 
 
Ligation of digested plasmid backbone and designed oligos was performed for 30 minutes at room 
temperature (Table 3.21.). 
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Reagent Volume (µl) 
Digested plasmid 10 
Oligos diluted 2 
T4 ligation buffer 10x 2 
T4 DNA Ligase 1 
H2O 5 
Table 3.21. Ligation of plasmid backbone with oligos. 
 
The last step was to digest the not ligated plasmid. For this purpose, the ligation mixture was 
combined with Plasmid Safe exonuclease and incubated for 30 minutes at 37°C and 30 minutes at 
70°C. The reaction components are shown in the table 3.22. 
Reagent Volume (µl) 
Ligation mix (see above) 11 
PlasmidSafe buffer 10x 1,5 
ATP 25 mM 0,6 
PlasmidSafe Exonuclease 1 
H2O Ad 15 
Table 3.22. Digestion of not ligated plasmid. 
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3.7.3 Transformation of plasmids into E. Coli 
To introduce the previously prepared plasmids into E. coli, 100 µl of competent DH5α strain were 
thawed for each plasmid. Subsequently, 3 µl of appropriate plasmid were added to each vial and 
the mixture was incubated for 10 minutes on ice. Next, incubation for 45 seconds at 42°C and 
another 2 minutes on ice was conducted. Transformed bacteria were plated onto agar plates 
containing Ampicillin and incubated overnight at 37°C.  
For each plasmid 3-6 colonies were inoculated into 5 ml of liquid LB medium containing 
Ampicillin in the concentration of 100 µg/ml and incubated at 37°C overnight. On the following 
day the isolation of DNA was performed using QIAprep Spin Miniprep Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instruction. 
To check if the insert was cloned properly, EheI restriction enzyme digestion was performed. Two 
suitable clones were sent for sequencing. The obtained results were compared with reference 
sequence using DNAMAN software. Suitable plasmids were used for the subsequent experiments.  
 
3.7.4 Determining Genome Targeting Efficiency using T7 Endonuclease I 
This approach is used to determine the targeting efficiency of previously designed gRNAs.  T7 
Endonuclease I recognize and cleaves non-perfectly matched DNA. Mismatches may occur, when 
the double DNA strand is cut and repaired through the non-homologous end joining (NHEJ) repair. 
Determination of efficiency was performed according to the manufacturer’s instruction (New 
England BioLabs, Ipswich, MA, USA). Briefly, 100ng of genomic DNA, either from cells 
transfected with oligos or the control cells, was used for each PCR reaction together with primers 
depicted in Table 3.23. Small amounts of PCR product were checked for the proper amplification 
and the residue was cleaned. Next, T7 Endonuclease I digestion was performed. The gRNAs with 
the highest targeting capacity were used during the next steps. 
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Primer name Sequence Binding site 
5’-1/2 T7 fwd TAAAGGGCATGCACCACCAT 5’-1: 75, 460 
5’-1/2/3 T7 rev TGCTCTTCTGCAGTGGCTAC 5’-2: 73, 462 
5’-3 T7 fwd ACAGCATGAAACTCCTCCCG 5’-3: 159, 331 
   
3’-1/2 T7 fwd TTAAATCCCGGCTGGTGGAG 3’-1: 197, 329 
3’-1/2/3 T7 rev AGCAAGTGCCATGACATCCA 3’-2: 189 ,337 
3’-3 T7 fwd GGTGAGTGAGCTGTAGCAGG 3’-3: 185, 255 
Table 3.23. Primers used for the PCR reaction to determine efficiency of Cas9 plasmids. 
 
3.7.5 Transfection and selection of clones. 
Two plasmids were identified for the usage in further genome editing:   
✓ 363 / fw: GAAAAGTAAGTTACCCTTAC TGG 
✓ 145 / rev: GTTCTAAAATAACTAGGGTA GGG. 
RIL-175 cells were transfected with both plasmids, using Lipofectamine 3000TM reagent, 
according to the manufacturer’s instructions. Subsequently, cells were selected using 2µg/mL 
Puromycin and 5 µg/mL Blasticidin for 48 hours. After selection, cells were incubated in culture 
medium until confluence was achieved. Next, cells were diluted to the concentration of 0,6 
cell/well and seeded into 96-well plates. To avoid cell aggregates, before seeding they were 
separated using a cell strainer. Single clones were grown until confluence. The gene expression 
was checked using PCR and the protein expression using western blot approach. 
 
3.7.6 2.8. The polymerase chain reaction (PCR) 
To identify the knockout of BAP31, generated clones were subjected to the PCR. I used a forward 
primer: 5’ACAGCATGAAACTCCTCCCG3’ and the reverse primer: 
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5’AGCAAGTGCCATGACATCCA3’. The cells were lysed with a QuickExtract DNA extraction 
reagent. I used the high fidelity DNA polymerase (Thermoscientific, Germany) according to the 
manufacturer’s instructions. 
For the colony PCR the Taq DNA Polymerase (ThermoFisher, Germany) was used according to 
the manufacturer’s instructions. A small amount of the fresh yeast was used as the template. 
3.8 MIGRATION OF CANCER CELLS 
3.8.1 The Boyden Chambers 
To analyze the migratory capacity of cancer cells they were cultivated in 6-well plates and starved 
for 24 hours before the experiment. Next, cells were trypsinized, counted and transferred to the 
upper chamber (8 µm pores) in a number of 1·105 cells/chamber in 200 µl of starvation medium. 
The lower chamber was filled with 600 µl of complete medium. Cells were allowed to migrate for 
5 hours. The number of migrating cells was calculated with ImageJ software using the “Cell 
Counter” plugin. 
 
3.8.2 Wound healing assay 
Cells were seeded in the 12-well plates in a number of 8·105 cells. On the next day, when the cells 
achieved the confluence, the scratch with the yellow tip was made in the middle of the well. Cells 
were washed twice with PBS and the hunger medium was added for the negative control and the 
complete medium in duplicates to the rest of the cells. The migration capability was verified after 
16 hours. 
3.9 LUCIFERASE DOUBLE REPORTER GENE ASSAY - SPLICING 
To verify the splicing capability of the cells, I transfected them with either Luc plasmid, which 
contained sequence for the Firefly luciferase, or Luc-I plasmid, which contained the insert between 
the coding sequence for the Firefly luciferase. As the control of the transfection efficiency we used 
the plasmid for the expression of Renilla luciferase. The transfection was conducted using 
Lipofectamine 3000 reagent as described in the section 2.6.2. Two days after the transfection, cells 
were lysed using passive lysis buffer provided within the Dual-Luciferase® Reporter Assay 
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System (Promega, Germany) kit. Cells were collected to the plastic 1,5ml tubes and centrifuged 
10 minutes at 14 000 rpm. 20 µl of supernatant was transferred onto the 96-well white plate. The 
measurement was conducted according to the manufacturer’s instructions using Orion II 
microplate luminometer (Titertek Berthold, Bad Wildbad, Germany). 
3.10 IMMUNOSTAINING AND CONFOCAL MICROSCOPY 
Cells were seeded into 8-well µ-Slide (Ibidi, Martinsried, Germany) in a number of 1·104 cells/well 
in culture medium and incubated at 37°C until about 60-70% of confluence. Next, cells were 
washed 3x with PBS+ (PBS solution containing Mg2+ and Ca2+ ions), fixed with 4% 
paraformaldehyde (PFA) in PBS for 10 minutes in room temperature. Once again cells were 
washed 3x with PBS and permeabilized with 0,1% Triton-X solution for another 10 minutes. Next, 
unspecific binding sites were blocked using 5% BSA in PBS solution for 30 minutes. An 
appropriate antibody was diluted 1:1000 in 1% BSA, applied onto the cells and incubated 
overnight at 4°C with shaking. On the following day, the samples were washed 3x, 5 minutes with 
1% BSA solution with shaking. Subsequently, appropriate Alexa Fluor® secondary antibodies 
were added in a concentration of 1:1000 in 1% BSA for another 2 hours in room temperature, 
shaking in the dark. After incubation time, cells were washed 3x with 1% BSA for 5 minutes in 
room temperature, shaking in dark. Before the end of the incubation, Hoechst33342 (Sigma-
Aldrich) in a 1:200 dilution was added to the cells. Next, cells were mounted with FluorSave™ 
mounting medium and the samples were covered with glass cover slides. Prepared samples were 
incubated overnight at 4°C, shaking in the dark. On the following day, pictures were acquired with 
either Zeiss LSM 510 Meta Confocal Microscope (Zeiss, Oberkochen, Germany) or Leica SP8 
Inverted scanning confocal microscope (Leica, Wetzlar, Germany). 
3.11 RECYCLING OF THE TRANSFERRIN RECEPTOR IN CANCER CELLS. 
To check the ability of cancer cells to recycle the transferrin receptor upon Soraphen A treatment, 
cells were seeded into 8-well µ-Slide (Ibidi, Martinsried, Germany). Following appropriate 
treatment, 100ng/ml of rhodamine-conjugated transferrin was applied onto the cells for 1h. 
Subsequently, cells were washed 3x with PBS+ and fixed with 4% PFA solution in PBS for 10 
minutes. Cells were washed 3x with PBS. Hoechst33342 (Sigma-Aldrich) in dilution 1:200 was 
added to the cells for 10 minutes. After additional 3 washing steps with PBS, FluorSaveTM medium 
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was added into each well and covered with glass cover slides. Prepared samples were incubated 
overnight at 4°C, shaking in the dark. On the following day pictures were acquired with Zeiss LSM 
510 Meta Confocal Microscope (Zeiss, Oberkochen, Germany). 
3.12 FORMATION OF LIPOSOMES CONTAINING PHOSPHATIDYLINOSITOL (PI) MIX 
First, 50µM of L-α-Phosphatidylinositol ammonium salt solution from bovine liver – PI mix 
(Sigma) dissolved in chlorophorm was added to a falcon. Next, the chlorophorm was evaporated 
with the stream of N2. The falcon was left for 30 minutes under the flow without the lid, to remove 
remains of chlorophorm. HEPES buffer (20µM, Table 3.24.) was added and the mixture was kept 
for 30minutes in water bath (37ºC) to hydrate PIs, from time to time vortexed. Appropriate volume 
of medium (with 2% FCS and 1% P/S) was added and incubated for additional 30 minutes in 
wather bath at 37ºC. Afterwards, PIs mixture was sonicated at room temperature for 30 minutes to 
reduce the size of liposomes formed during the phase of hydratation. Immediately after the 
sonication, the prepared PI mix was put on the cells. 
 
 
 
 
 
Table 3.24. HEPES buffer composition. 
3.13 RESCUE OF THE SORAPHEN A TREATMENT EFFECT 
Cells were seeded in 24-well plates (0,5·105/well) in DMEM medium with 10% FCS and 1% P/S. 
After the attachment of the cells, they were stimulated with 10µM of Soraphen A for 24 hours in 
DMEM with 2% of FCS and 1% of P/S at 37ºC. Subsequently, PI mix mentioned above was 
prepared for stimulation.  
Cells were treated with the PI mix for 16 hours. After this time, PI was removed from the cells, 
medium with 2% FCS and 1% P/S was added and the cells were left for additional 2 days to freely 
1 M HEPES, pH = 7.0  
HEPES          119.15 g 
NaOH    to adjust pH 
H2O  
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proliferate. The rate of proliferation was checked with the CellTiter-Blue® reagent (Promega, 
Madison, WI, USA). 
 
3.14 IDENTIFICATION OF BAP31 INTERACTION PARTNERS APPLYING YEAST 2 
HYBRID APPROACH 
To identify BAP31 interaction partners we decided to apply the Yeast 2 Hybrid approach as 
described before (Chien et al., 1991). For this purpose, we used the Matchmaker Gold Yeast Two-
Hybrid System (Takara Bio Group, CA, USA) according to the manufacturer’s instruction. Briefly, 
we cloned a bait insert – sequence for BAP31 – into pGBKT7 vector provided with the kit, using 
BamHI and EcoRI restriction enzymes. Next, the obtained plasmids were sequenced to confirm 
that the insert is in-frame with the vector.  
Subsequently, the bait-plasmid was transformed into the Yeast strain – Y2HGold. After the 
selection on DDO (Double Dropout, SD/-Leu/-Trp) plates, a prominent yeast colony was 
inoculated into liquid DDO medium and incubated overnight, shaking at 30ºC. On the following 
day the culture was harvested and the bait-containing Y2HGold strain was mated with the library 
in Y187 Yeast Strain. Next, mated yeast were seeded on plates with increasing selectivity, namely: 
DDO, DDO/X (DDO + X-α-Gal) ending up on DDO/X/A (DDO/X + Aureobasidin A). Colonies, 
which grew on DDO/X/A plates and turned blue were diluted in water and stamped onto each 
selection plate – DDO, DDO/X and DDO/X/A. Yest colonies which were growing and turning 
blue on DDO/X/A but not at DDO and DDO/X plates were used for the colony PCR.  
The size of PCR product was compared using agarose gel electrophoresis and plasmids which 
seemed to contain the inserts of a different size were selected, purified and sent for the sequencing. 
The results were checked using BLAST tool. Hits were tested towards auto-activation. The 
interaction partner of BAP31 protein was identified. 
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4. AIMS OF THE STUDY 
Following the promising results of work of Dr. Fabian Koczian in his doctoral thesis, I decided to 
extend the topic of PS89 driven chemo-sensitization by different types of leukemia applying 
various cytostatics and combining them with PS89. Moreover, following promising results of 
previous work, I wanted to focus on the function of BAP31 in cancer cells.  
In my opinion the most interesting points were:  
1. To show the potential of combination therapy using cytostatics with the chemo-sensitizing 
compound – PS89 in different types of leukemia models. 
2. To elucidate the mechanism of induction of apoptosis in different leukemia models treated 
with combination of PS89 with various cytostatics. 
3. To investigate the functional results of lack of BAP31 expression on cancer cells. 
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5. RESULTS 
5.1 INVOLVEMENT OF BAP31 IN THE CHEMO-SENSITIZATION OF VARIOUS 
LEUKEMIA TYPES TOWARDS COMMONLY USED CHEMOTHERAPEUTICS 
 
5.1.1 Combination of various cytostatics with PS89 enhances their anti-cancer properties 
in different leukemia types but not in hematopoietic cells. 
Treatment of leukemia is difficult due to the formation of chemo-resistance. Moreover, there is a 
great spectrum of side effects which occur upon the chemotherapy. Thus, it is of a great importance 
to focus on combinatorial therapies, which can decrease the side effects of common treatments and 
re-sensitize cell which have formed a resistance towards the chemotherapeutics. Accordingly, I 
decided to test various cytostatics in combination with the small molecule – PS89, to introduce a 
new approach for the treatment of various types of leukemia. 
To test the capability of proliferation of the acute myeloid leukemia (AML) cell line out of the 
single cell, I applied the colony formation assay (Figure 5.1.). We decided to use one of the drugs 
commonly used in the AML treatment – 6-Mercaptopurine (6-MP). Cells treated with DMSO as 
well as PS89 did not show a decrease in the colony number. The treatment with 6-MP alone was 
more effective. What is interesting, after the addition of PS89 together with 6-MP (+/+), we can 
observe a synergistic effect on the inhibition of colony formation. The significance was tested 
using the BLISS independence model with the result value of 1,78. 
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Figure 5.1. The effect of the combinatorial treatment on the colony formation capability of the 
AML cell line HL-60. Cells were pre-treated for 24 hours with either 25 µM of PS89, 100 µM of 
6-Mercaptopurine (6-MP) or the combination. Next, cells were seeded in the number of 1·104/well 
and left to proliferate for 7 days. The data are presented as colony formation units (CFU). The 
graph shows three independent experiments. The error bar shows standard deviation. Data were 
tested applying one-way ANOVA statistic. 
 
I also checked the influence of combinatorial treatment on the induction of apoptosis in various 
leukemia cell lines. Therefore, we treated Jurkat (ALL) and HL-60 (AML) cells with increasing 
doses of 6-MP and 25µM of PS89 for 48 hours to test the half maximal effective concentration 
(EC50) value for the drug alone and in the combination with the potential chemo-sensitizer (Figure 
5.2). We could show, that combination of Mercaptopurine (6-MP) with PS89 led to the decrease 
of the EC50 value of Mercaptopurine in Jurkat cells from 2,9µM to 1,3µM and in HL-60 from 
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511,8 µM to 128,8 µM. These values have been obtained through the application of a nonlinear 
regression model.  
 
Figure 5.2. Chemo-sensitizing effect of PS89. Combination of Mercaptopurine (6-MP) with PS89 
leads to the decrease of the EC50 value in comparison to Mercaptopurine alone in Jurkat cells 
(A) as well as in HL-60 (B). Cells were treated with increasing doses of Mercaptopurine with or 
without addition of 25µM of PS89 for 48 hours. Graphs show three independent experiments. The 
error bars show standard deviation. EC50 value was calculated applying nonlinear regression 
model. 
 
I analyzed also the combination of PS89 with Dexamethasone (DEX). DEX is a corticosteroid 
commonly used for the treatment of various cancer types, including ALL and AML. Figure 5.3. 
presents the effect of the combinatorial treatment on the induction of apoptosis in HL-60 and Jurkat 
cell lines. Stimulation of cells for 48 hours with combination of cytostatic with putative chemo-
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sensitizer led to the significant increase in the apoptosis rate in comparison to the treatment with 
PS89 or DEX alone.  
 
Figure 5.3. Induction of apoptosis in cells treated with combination of PS89 and Dexamethasone 
(DEX). HL-60 as well as Jurkat cells were treated with either 25µM of PS89, 250 µM of DEX or 
combination of those two for 48 hours. The percent of apoptosis was assessed as the PI-positive 
percent of acquired events. Graph shows three independent experiments. Error bars show the 
standard deviation. Data was tested applying one-way ANOVA statistic. 
 
As the potential of the therapy is connected also to generated side effects, I asked ourselves if 
combinatorial treatment could be harmful for CD34+ cells. This protein is a marker for early 
hematopoietic cells, which are crucial in the formation of blood cells, therefore very important in 
the process of recovery after chemotherapy.  
To show that combinatorial treatment is not harmful for hematopoietic cells, I isolated the 
Peripheral Blood Mononuclear Cells (PBMCs), where about 0,1% of cells are CD34+, from the 
blood of healthy volunteers as described in the section 3.2.3 and treated them with the combination 
of cytostatic and chemosensitizer.  
It has been tested before and showed in the doctoral thesis of Dr. Fabian Koczian, that combination 
of 20 µM of DNR and 25 µM PS89 leads to a synergistic effect in the induction of apoptosis in 
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PDX cells with BLISS values of 1,1 – 1,7 depending on the patient. Therefore, I showed that the 
same setting is not harmful for the cells expressing CD34 protein (Figure 5.4). The induction of 
specific apoptosis oscillated between 0% and 3% in cells treated either with PS89, Daunorubicin 
or combination. Therefore, we can conclude that this treatment is not harmful for hemopoietic cells 
characterized by CD34 expression. 
 
Figure 5.4. The influence of the treatment with Daunorubicin and PS89 on CD34+ cells. Cells 
were treated for 48 hours with 25 µM of PS89, 20µM of Daunorubicin or the combination. The 
stopping gate was set to 25 000 of FITC-positive cells. The graph shows three independent 
experiments. The error bars show standard deviation. Data was tested applying one-way ANOVA 
statistic. 
 
5.1.2 Caspase-8 and BAP31 activation constitutes a platform for the induction of apoptosis 
in leukemia cells upon the treatment with the combination of PS89 and cytostatic. 
It was shown that PS89 targets PDI (Eirich et al., 2014). However, the research of Dr. Fabian 
Koczian, which is shown in his doctoral thesis, has indicated that silencing of PDI is not mimicking 
the effect of PS89 treatment. Moreover, in his thesis, he has shown further proteomics analysis, 
applying the Activity Based Protein Profiling (ABPP) approach. These data revealed that BAP31 
is another promising target of PS89, which is also involved in ER homeostasis. Therefore, our 
further research focused on this protein. 
As described before, Caspase-8 and BAP31 constitute a platform for the induction of apoptosis 
(Wang et al., 2011). Therefore, I tested the activation of BAP31, which is expressed in the amount 
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of cleaved protein, and Caspase-8 in an ALL cell line - CCRF-CEM (Figure 5.5). The treatment 
was applied for either 24 or 48 hours. Already after 24 hours we could observe a decrease in the 
total form of both BAP31 and Caspase-8 when cells were treated with the combination of 
Vincristine (VCR) and PS89. However, the effect was the most prominent after 48 hours of 
treatment with the combination. Then we could see also the cleavage product of BAP31, what was 
not possible in 24 hours setting. This confirms, that the addition of PS89 and the cytostatic, but 
not the substances alone, led to the activation of both – Caspase-8 and BAP31. 
 
Figure 5.5. CCRF-CEM cells were treated with 1 nM of Vincristine (VCR), 25 µM of PS89 or the 
combination for either 24 or 48 hours. Next, they were subjected to western blot to analyze 
activation of Caspase-8 and BAP31. The experiment was performed three times, independently. 
Figure shows one, representative blot. 
 
I could confirm that the mode of action is the same when we apply PS89 and VCR treatment to 
the Patient Derived Xenograft (PDX) cells. This type of cells is obtained from human patients and 
cultivated in immuno-deficient mice. To isolate the human cells for the experiments, it is necessary 
to use either spleen or bone marrow of mouse. This approach allows us to test our setting in a 
primary environment in comparison to the regular cell lines growing in vitro. Already 24 hours of 
exposition to the combination of substances was sufficient to show the decrease in the total form 
of both Caspase-8 and BAP31 (Figure 5.6). This decrease shows indirect proof for the cleavage of 
those two proteins. Therefore, we can conclude that also in this cell line treatment with 
combination of PS89 and Vincristine induced activation of Caspase-8 as well as BAP31. 
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Figure 5.6. Activation of Caspase-8 and BAP31 in Patient Derived Xenograft (PDX) cells. PDX 
cells were treated with 1nM of Vincristine (VCR), PS89 or the combination for 24 hours. Next, 
they were subjected to western blot to validate activation of Caspase-8 and BAP31. This 
experiment was performed three times. The figure shows one, representative blot. 
 
5.1.3 The pro-apoptotic cross-talk between Endoplasmic Reticulum (ER) and 
mitochondria. 
According to the literature the Caspase-8 and BAP31 cleavage is followed by the release of 
calcium from the ER leading to the transfer of apoptotic signal further to the mitochondria (Wang 
et al., 2011; Iwasawa et al., 2011; Grimm, 2012). Therefore, we tested the combination of PS89 
with DNR or VCR in the HL-60 (Figure 5.7. A) and CCRF-CEM (Figure 5.7. B) cells for 24 and 
48 hours, and in PDX (Figure 5.7. C) cells for 24 hours. We showed, that the treatment with PS89 
and drugs alone was not very effective concerning the induction of a calcium release. However, 
after the treatment of both HL-60 and CCRF-CEM cells for 48 hours with the combination, we 
observe a significant increase in the cytosolic calcium level. The same is true already after 24 hours 
treatment of the PDX cells with VCR and PS89. It means, that the activation of Caspase-8 and 
BAP31 leads to subsequent calcium release from ER to cytoplasm, what is an important signaling 
event concerning induction of apoptosis, as described above. 
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Figure 5.7. The treatment of AML (A), ALL (B) and PDX (C) cells with combination of PS89 with 
cytostatic led to the increase in the level of cytosolic calcium. Cells were treated for 24 or 48 
hours. Next, loaded with fluorescent dye Cal-520. Data were assessed by flow cytometry. A. 
Treatment of HL-60 cells with combination of Daunorubicin (20µM) and PS89 (25µM) of HL-60 
for 24 (grey) and 48 (dark grey) hours. B. Treatment of CCRF-CEM cells with combination of 
PS89 (25µM) and VCR (1nM) for 24 (grey) and 48 (dark grey) hours. C. PDX were treated with 
combination of VCR (1nM) and PS89 (25µM) for 24 hours. The graph shows three independent 
experiments. Error bars represent standard deviation. Data was tested applying one-way ANOVA 
statistic. 
 
Following described mechanism of induction of apoptosis, calcium release triggers apoptotic 
events in the mitochondria. The mitochondrial membrane potential (ΔΨm) is linked to the outer 
mitochondrial membrane permeabilization, what leads to cell death induction through the release 
of the cytochrome c (Wang et al., 2011). Therefore, we checked if our treatment induces a release 
of the mentioned protein from mitochondria to the cytoplasm.  
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For the purpose of this experiment, we used the CCRF-CEM cell line and the 
mitochondrial/cytoplasmic fractionation approach. As it is shown in Figure 5.8, the treatment with 
both PS89 and VCR for 48 hours led to the release of cytochrome c to the cytoplasm. The Voltage-
Dependent Anion Channel (VDAC) was used as a mitochondrial marker. We can observe, that the 
cytoplasmic fraction was not contaminated with mitochondria, but still cytochrome C is present in 
the cytoplasmic fraction in cells treated with combination of PS89 and VCR. We can conclude, 
that cytochrome C is released to the cytoplasm as the result of calcium release and loss of 
mitochondrial membrane potential. 
 
Figure 5.8. Release of cytochrome C to cytoplasm. CCRF-CEM cells were treated with the 
combination of PS89 (25µM) and Vincristine (VCR, 1nM) for 48 hours. Next, they were subjected 
to cytoplasm/mitochondria fractionation and western blot. Fractions of cytoplasm and 
mitochondria were checked for the cytochrome C expression. VDAC was used as a marker for 
mitochondrial fraction. Experiment was performed 3 times, independently. Graph shows one, 
representative blot. 
 
The loss of the mitochondrial membrane potential induced through Ca2+ signalling, leads also to 
the release of Reactive Oxygen Species (ROS) (Tait et al., 2010; Yaday et al., 2015). Therefore, 
we tested cytosolic ROS concentration in CCRF-CEM and HL-60 cell lines (Figure 5.9.). Once 
again, the data were consistent. The most prominent release of ROS was observed upon a 
combinatorial treatment for 48 hours in both tested cell lines. This leads us to the conclusion, that 
the mitochondrial damage occurring after the treatment with combination of potential chemo-
sensitizer with cytostatics results in accumulation of ROS, what provokes further disturbance of 
ER redox homeostasis, closing the feedback loop. 
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Figure 5.9. Accumulation of Reactive Oxygen Species (ROS) upon treatment with combination. 
Cells were treated for either 24 (grey) or 48 (dark grey) hours, next loaded with the redox sensitive 
dye Carboxy-H2DCFDA and analyzed by flow cytometry. The values represent the mean of 
fluorescence intensity normalized towards control. A. treatment of CCRF-CEM cells with 
combination of 1nM of VCR and 25 µM of PS89. B. Treatment of HL-60 with combination of 20 
µM of DNR and 25 µM of PS89. Error bars show standard deviation. Experiment was performed 
three times, independently. Data was tested applying one-way ANOVA statistic. 
 
5.1.4 The cytochrome c release induces an activation of the death protease. 
The release of cytochrome c to the cytoplasm triggers the activation of the death protease – 
Caspase-3 (Zou et al., 1997; Li et al., 1997) and further leads to the cleavage of Poly(ADP-Ribose)-
Polymerase (PARP) enabling apoptosis (Decker et al., 2000). Therefore, we tested CCRF-CEM 
and HL-60 cell lines treating them with either VCR or 6-MP in combination with PS89 for 24 
hours (Figure 5.10). We showed, that already after this period of stimulation with combinatorial 
treatment both PARP and Caspase 3 are cleaved. These data confirm that treatment with the 
combination of potential chemo-sensitizer and cytostatic, but not the drugs alone, leads to the 
activation of the apoptotic pathway. 
   
 
58 
 
 
Figure 5.10. Treatment of leukemic cells leads to the activation of apoptotic pathway. Cells were 
treated with cytostatics, PS89 alone or combination for 24 hours. Next, they were subjected for 
western blot analysis for PAPRP and Caspase-3 activation. A. Treatment of CCRF-CEM cells with 
combination of 1nM of VCR and 25 µM of PS89 leads to the activation of apoptotic pathway. B. 
Treatment of HL-60 cells with combination of 100µM of 6-MP and 25µM of PS89 induces 
activation of PARP and Caspase-3. 
 
5.1.5 The summary of the effect of BAP31 activation on the chemo-sensitization of leukemic 
cells towards cytostatic treatment. 
In summary, we proved that the activation of Caspase-8 and further BAP31 cleavage led to an 
increase in the cytosolic calcium level and loss of mitochondrial membrane potential. The latter 
one enabled release of Reactive Oxygen Species and cytochrome C to the cytoplasm. When the 
ROS release triggered further ER-stress in a positive feedback loop, cytochrome c present in the 
cytoplasm activated the apoptotic stimuli like caspase-3, leading to the PARP cleavage. All these 
events resulted in the induction of apoptosis.  
We proved, that chemo-sensitization of cells with PS89 gave significantly better results in 
induction of apoptosis in comparison to the treatment with the estabilished chemotherapeutics 
alone. Therefore, we believe that this substance is a great candidate for further testing concerning 
the combinatorial treatment. These data could be confirmed regardless of the cell line or the 
cytostatic used during the experiments. It confirms, that the mechanism of action is the same in all 
the tested settings. 
These data have been published in Haematologica on October 2018 under the title: Targeting The 
ER-Mitochondria Interface Sensitizes Leukemia Cells Towards Cytostatics by: Fabian Koczian, 
Olga Nagło, Jan Vomacka, Binje Vick, Phil Servatius, Themistoklis Zisis, Britta Hettich, Uli 
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Kazmaier, Stephan A Sieber, Irmela Jeremias, Stefan Zahler and Simone Braig (Doi: 
10.3324/haematol.2018.197368). 
5.2 THE FUNCTION OF BAP31 IN HEPATOCELLULAR CARCINOMA 
Inspired by the results of investigation of the effect of PS89 on BAP31, we asked ourselves what 
kind of function this protein has in cancer. As the literature focus on BAP31 as a chaperon protein 
present in the ER and the inducer of apoptosis, we decided to go deeper into its function in cancer 
cells which is not elucidated to the detail, yet. Therefore, we generated a stable knockout of BAP31 
in the hepatocellular carcinoma mouse cell line – RIL-175, using CRISPR/Cas9 technique. This 
provided us a tool for a deeper understanding of the function of BAP31. 
 
5.2.1 Generation of the BAP31 deficient cell line. 
To establish a stable BAP31 knockout in RIL-175 cell line, we followed the literature (Ran et al., 
2013). We decided to remove exon 3 to obtain the mRNA for the truncated protein, which would 
be subsequently subjected to the nonsense-mediated decay (NMD) pathway. This should result in 
the knock out of the protein of our interest.  
For our further investigation, we decided to use two controls: the wild type cell line (WT) and the 
cell line generated out of the clone which went through the CRISPR/Cas9 technique, but the 
knockout was not successful (crWT). Moreover, to exclude the off-target effects, we used two 
different cell lines generated out of the knock out clones – KO1 and KO2.  
To be certain, that the knock out was successful, we confirmed it applying three methods. First, 
we compared the size of the PCR products and observed that the size of the PCR product for the 
knockout cells was twice smaller than one of the wild type cells (Figure 5.11.A). Second, we 
sequenced this product and compared with the reference sequence. This has shown, that almost 
half of the sequence is missing in clones declared as the knockouts. Third, we checked the protein 
expression applying western blot approach and saw, that there is no more expression of BAP31 in 
knockout cell lines (Figure 5.11.B). 
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Figure 5.11. The confirmation of BAP31 knockout in RIL-175. In further investigation we used 
four cell lines: wild type (WT) and the unsuccessfully CRISPR-ed clone (crWT) as the controls, 
and two BAP31 knock out clones to exclude the effect of the off-targets (KO1 and KO2). A. The 
PCR product of the wild type and BAP31 knockout. B. Expression of BAP31 in the wild type and 
knockout cell lines evaluated by western blot. 
 
5.2.2 Knock out of BAP31 had no influence on the morphology of cancer cells. 
Our first concern was the morphology of the generated cell lines. Any changes in the appearance 
of the cells could give us a hint if e.g. BAP31 is important for the cytoskeleton composition or cell 
attachment. Therefore, we took a closer look into the shape and behaviour of RIL-175 cells in 
comparison to the generated clones in culture, but we could not see any morphological changes 
between the cell lines (Figure 5.12). 
 
Figure 5.12. The morphology of RIL-175 cells is not affected by knockout of BAP31. Pictures were 
taken using light microscope. 
 
5.2.3 There is no influence of BAP31 deficiency on the proliferation of cancer cells. 
High proliferation capacity of cells is one of the hallmarks of cancer. Therefore, we wanted to 
know if the knockout of BAP31 has an influence on the growth of RIL-175. 
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We started with CellTiter-Blue, which relays on the metabolic activity of cells (Figure 5.13.A). In 
this assay we could not see any changes in the proliferation of wild type and knockout cells. To 
exclude the possibility that we could not see an effect on the proliferation because the cellular 
metabolism was changed, we used ViCell device to count the cells (Figure 5.13.B). After 72 hours 
of proliferation, cells were detached and counted with ViCell device. Once again, we could not 
observe any changes in the number of BAP31 knockout in comparison to wild type cells. The last 
approach – using an xCELLigence device – relayed on the disruption of the transduction of 
electrical impulses through the plate (Figure 5.13.C). Also, this experiment showed, that there is 
no difference in the proliferation capacity between cells expressing and lacking BAP31. In 
summary, even though we have checked the metabolism, number of cells and the growth area, we 
could not notice any significant changes in the proliferation capability of tested cells. 
 
Figure 5.13. BAP31 knockout has no influence on the proliferation of RIL-175 cells. A. The 
proliferation rate of WT and KO cells was quantified with CellTiter-Blue reagent after 72 hours. 
Data was normalized towards the “Day 0” control. B. Cell were proliferating for 72 hours. The 
number of cells was assessed using the ViCell device at the end of the experiment. Data is shown 
as a percent of control. C. An electronic readout called impedance non-invasively quantify 
adherent cell proliferation and viability in real time. The cells are seeded in standard microplates 
that contain microelectronic sensor arrays. The interaction of cells with the electronic biosensors 
generates a cell-electrode impedance response that not only indicates cell viability but also 
correlates with the number of the cells seeded in the well. 
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We confirmed these data testing the cell cycle frequency of generated cell lines (Figure 5.14).  
Using the FlowJo software, we applied the Watson Pragmatic univariate model. Fitting the curves 
to the appropriate cell cycle phase returned the values of each cell cycle phase. We could not 
observe any cell cycle arrest neither in the wild type nor knockout cells. These data are consistent 
with the experiments testing the proliferation capability of cancer cells upon the BAP31 knockout, 
supporting the statement that depletion of BAP31 has no influence on the proliferation of cancer 
cells. 
 
Figure 5.14. Comparison of the cell cycle frequency in the wild type and knock out BAP31 in RIL-
175 cancer cells. The DNA content was measured by flow cytometry, assessing the signal from 
propidium iodide. Cell cycle frequency was analyzed applying the Watson pragmatic model using 
FlowJo software. 
 
5.2.4 The migration is also not affected by BAP31 knockout. 
Next to the high growth capacity, migration is a hallmark of cancer as well. Therefore, we applied 
two approaches to test the capability of cancer cells expressing and lacking the BAP31 protein to 
migrate. Figure 5.15.A shows the result of the experiment using Boyden Chambers, when Figure 
5.15.B shows the simple scratch assay. Both experiments confirm the same conclusion – there are 
no consistent results of knock out of BAP31 in cancer cells on their migratory abilities. 
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Figure 5.15. BAP31 knockout does not influence the capability of cancer cell line RIL-175 to 
migrate. A. Cell movement abilities have been tested with Boyden Chambers approach. Boyden 
chambers with 5µm pores were used. Cells were migrating for 5 hours. Cell number was assessed 
with ImageJ software. B. The wound healing assay has been performed to check the migration 
capability of cells expressing and lacking BAP31. When confluence was achieved, a scratch was 
done with a pipet tip. Cells were allowed to ”heal the wound” for 16 hours. Next, cells were stained 
for the contrast with crystal violet. Pictures were taken under the light microscope. Data was 
tested using one-way ANOVA statistic. 
 
5.2.5 Knock out of BAP31 does not affect the attachment of cancer cells. 
We also tested the attachment of the cells. To compare the ability of wild type and knockout cells, 
we decided to use two different approaches – a crystal violet staining after 30 minutes of 
attachment (Figure 5.16.A) and the xCELLigence up to 120 minutes (Figure 5.16.B). However, 
the knockout of BAP31 had no significant influence also on this function of RIL-175 cell line. 
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Figure 5.16. The attachment of RIL-175 cells expressing BAP31 in comparison to the BAP31 
knockout cells. A. Cells stained with crystal violet after 30 minutes of attachment. B. xCELLigence 
analysis of the attachment 30 minutes after the seeding. 
 
5.2.6 Identification of BAP31 interaction partners. 
As we could not observe any functional differences between cells expressing and lacking BAP31, 
we decided to check for the proteins which interact with the one of our interest. To identify BAP31 
interaction partners, we used a Yeast Two Hybrid technique.  
In this approach a bait protein is expressed as a fusion to the Gal4 DNA-binding domain (DNA-
BD; pGBKT7 vector; Figure 5.17.B), while libraries of prey proteins are expressed as fusions to 
the Gal4 activation domain (AD; pGADT7 vector; Figure 5.17.B; Fields & Song, 1989; Chien et 
al. 1991). When the bait and the prey proteins interact, the AD and DNA-BD domains are in the 
proximity (Figure 5.17.A). This results in the activation of transcription of four independent 
reporter genes: AUR1-C, ADE2, HIS3, and MEL1. In the yeast strain Y2HGold, activation of the 
reporters occurs only in a cell that contains proteins which interact and bind to the Gal4-responsive 
promoter. Therefore, it is possible to select the colonies in which the interaction occurs, seeding 
them on the plates with increasing selection capacity. 
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Figure 5.17. The Yeast Two Hybrid technique. A. The interaction between the bait (BAP31) and a 
prey (TRA2B) leads to the activation of transcription of reporter genes, as the GAL4 DNA binding 
domain (DNA-BD) and the GAL4 activation domain (AD) are in the proximity. B. Plasmids 
illustrating the bait and the prey cloned into the appropriate vectors. 
 
In our investigation, I used BAP31 as a bait. Seeding the yeast on the selective plates allowed us 
to identify the colonies with the potential interaction of BAP31 with a prey. Those colonies were 
subjected to colony PCR and the bands of a different size were identified and sequenced. Out of 
25 sequenced colonies, I obtained two hits: Transformer 2 Beta Homolog (TRA2B) and SNARE-
associated protein Snapin (SNAPIN). Next, we needed to confirm that the prey plasmid does not 
autonomously activate the reporter genes in Y2HGold, in the absence of the bait protein.  
Figure 5.18. shows two settings which we applied to test our prey plasmids towards auto-
activation. In one setting we have just the prey expression (pGBKT) and in the second expression 
of both bait and prey proteins (pGBKT-BAP31). This interaction between bait and prey should 
activate the reporter genes. One of those is MEL1 coding α-Galactosidase which can hydrolize X-
α-Galactose (X). This reaction results in the blue product. One more reporter gene is a resistance 
to Aureobasidin A (A). There are two more reporter genes – Adenine and Histidine. Yeast cannot 
grow on the medium without these amino acids. As QDO plate is lacking Tryptophan and Leucine 
(which are coded on the vectors) as well as Adenine and Histidine which are reporter genes, yeast 
is not able to grow on this plate if there is no expression of reporter genes. If the reaction between 
prey and bait occurs, we can observe growing colonies which turn blue. Unfortunately, the plasmid 
for SNAPIN, even if there is no interaction with bait, seems to activate the reporter genes. 
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Therefore, we need to assume that there was no interaction between SNAPIN and BAP31 and had 
to exclude SNAPIN from our investigation. 
 
 
Figure 5.18. Test of the prey vector for the autoactivation. Prey plasmids were transformed into 
yeast together with empty bait vector (pGBKT7) or bait plasmid containing sequence for BAP31 
(pGBKT7-BAP31). Only, when the interaction between bait and prey proteins occurs, the yeast 
should be able to grow on the selective plate, due to the activation of reporter genes. As prey 
plasmid containing sequence for SNAPIN was able to activate reporter genes when there was no 
bait, we call it auto-activation. It was not possible to go on with this hit, because there was most 
likely no interaction between BAP31 and SNAPIN. 
 
Applying co-immunoprecipitation assay we could confirm, that BAP31 interacts with TRA2B. 
Figure 5.19. shows the result of immunoprecipitation of BAP31. The immune-precipitate of 
BAP31 was next subjected to western blot. We were successful to show, that in the mixture of 
proteins which interact with BAP31 we could also show presence of TRA2B. It re-confirmed the 
results obtained in yeast and established that interaction between BAP31 and TRA2B occurs also 
in mammalian cells. 
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Figure 5.19. BAP31 and TRA2B interact also in mammalian cells. Cytoplasmic fraction of RIL-
175 cells was incubated with µMACSTM Protein G MicroBeads and BAP31 antibody. 
BAP31precipitate was subjected to western blot and analyzed for TRA2B expression. IgG control 
for rabbit was used to exclude bands representing light and heavy chain of antibody used for 
immunoprecipitation of BAP31. 
 
5.2.7 The functional result of lack of the interaction between BAP31 and TRA2B. 
Following our discovery, that BAP31 interacts with TRA2B, we decided to check the function 
regulated by TRA2B. This protein has been reported as an activator of splicing (Grellscheid et al., 
2011; Elliott et al., 2012) as well as the alternative splicing regulator (Daoud et al., 1999; Matlin 
et al. 2005; Watermann 2006). We hypothesize that BAP31 captures TRA2B in the cytoplasm, 
what inhibits its function preventing its nuclear translocation. Following this hypothesis, lack of 
BAP31 expression should result in increase of TRA2B activity. Therefore, we decided to check 
the splicing capacity of the generated BAP31 knockouts.  
To investigate if the changes in splicing occur in cells lacking BAP31 we used the Luciferase 
Reporter Gene Assay. Cells were transfected with the plasmid containing the sequence coding 
luciferase interrupted via an intron (Figure 5.20. A). To normalize the data between the cell lines 
to the normal transcription level, we used the plasmid which coded luciferase without any 
additional inserts. 
In this experiment we could show, that cells which are not expressing BAP31 show higher splicing 
capacity (Figure 5.20.B). To confirm, that this function is affected due to TRA2B activity, we 
silenced this protein by siRNA in the experimental cells and normalized data to the wild type 
control expressing TRA2B. Clearly, knock out of TRA2B rescued the increase in splicing 
capability of cells lacking BAP31 (Figure 5.20.C). Therefore, we can state that knock out of 
BAP31 in RIL-175 led to the increase in splicing capacity, what is connected to TRA2B protein. 
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Figure 5.20. Knock out of BAP31 leads to the increase in splicing capacity of RIL-175 cells. A. 
The schema of plasmids used in luciferase reporter gene assay. B. Cells lacking BAP31 show 
increased splicing. Data was assessed with Luciferase reporter gene assay and normalized 
towards basal transcription level of each cell line. C. Silencing of TRA2B rescues the increase in 
splicing ability of BAP31 knockout cells. First, cells were transfected with siRNA for 24 hours, 
next transfected with plasmids for another 48 hours. After this time luciferase content was verified. 
Data was tested using one-way ANOVA statistic. 
 
5.2.8 Influence of increased splicing on the signaling in cancer cells. 
As described above, we investigated that the splicing capacity of RIL-175 cells is affected due to 
the lack of BAP31 expression. Therefore, we wanted to elucidate the signaling consequences of 
this change. Best et al. (2014), have investigated the Tra2-dependent genes and identified 53 
proteins which were associated with Tra2 expression. Out of those genes Protein Arginine 
Methyltransferase 2 (PRMT2) seemed to be interesting concerning the cancer, as it is a regulator 
of Nuclear Factor κB (NFκB). Therefore, we have checked the expression of PRMT2 in cells 
expressing and lacking BAP31 (Figure 5.21A). We could confirm, that the expression of PRMT2 
was increased in BAP31 knockout cells. This was consistent with the increase in splicing capacity 
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of cells lacking the protein of our interest. Moreover, we silenced TRA2B in all the cell lines and 
checked the expression of PRMT2 (Figure 5.21B). Treatment of cells with siRNA directed against 
TRA2B led to the rescue of increase in PRMT2 expression in BAP31 knockout cells. 
 
Figure 5.21. The expression of PRMT2 protein in RIL-175 expressing and lacking BAP31. A. 
Knock out of BAP31 leads to the significant increase in the expression of PRMT2. Expression was 
validated by western blot and quantified using Image Lab software. B. Silencing of TRA2B rescues 
the increase in expression of PRMT2. Cells were transfected with siRNA for 72 hours. After this 
time the expression of PRMT2 was verified by western blot and quantified with Image Lab 
software. Data was tested using one-way ANOVA statistic. 
 
Following these hints, we examined the downstream of PRMT2 protein, namely NFκB signaling. 
According to the literature, PRMT2 regulates the NFκB signaling pathway through the nuclear 
accumulation of IkBα (Ganesh et al., 2006; Dalloneau et al., 2011).  
To confirm our hypothesis that increased expression of PRMT2 leads to changes in the NFκB 
signaling also in our setting, we decided to check the nuclear accumulation of IkBα in the nucleus 
(Figure 5.22). The mechanism of regulation of NFκB by PRMT2 involves the accumulation of 
IkBα in the nucleus, therefore we applied the cytosol/nuclear fractionation approach to visualize 
this increase. As it is shown in the BAP31 knockout cells there is an increase of IkBα in the 
nucleus. Histone 3 (H3) was used as a marker for the nuclear and Tubulin for the cytoplasmic 
fraction. These data confirm that in cells lacking BAP31 more IkBα accumulates in the nucleus in 
comparison to the control, wild type cells. 
   
 
70 
 
 
Figure 5.22. NFκB signaling in wild type vs knockout cells. Cytoplasm/nucleus fractionation was 
applied to check the expression of IkBα in the nucleus. Histone 3 (H3) was used as a nuclear 
marker to verify the quality of fractionation. Tubulin α was used as a cytoplasmic marker. 
Quantification was performed using Image Lab software. Data was tested using one-way ANOVA 
statistic. 
 
As NFκB is connected to the autophagy process in cancer cells (Zhu et al., 2017), we investigated 
if also in our model we can observe the difference between the wild type and BAP31 knockout 
cells. It is known, that autophagy is a very dynamic process, therefore it is not possible to just 
check the expression of the proteins associated with autophagy. Zhang et al. (2018) provide an 
instruction how to properly evaluate the autophagic flux. Rephrasing this article, state of the art 
method requires to use the inhibitor of autophagy (we used Concanamycin) next to the control 
cells. Subsequently, it is recommended to subtract the amount of expressed control protein from 
the one treated with the inhibitor. Then, the result of the equation gives the amount of autophagic 
flux. 
I decided to check the expression of LC3-II as well as p62. Both proteins, upon described analysis, 
showed decreased autophagic flux in cells with BAP31 knockout in comparison to the wild type 
(Figure 5.23 A and B). Moreover, I overexpressed LC3-II conjugated with EGPF, what enabled 
us to show the decrease in the formation of autophagosomes in cells lacking BAP31 (Figure 5.23. 
C). These data show, that a decrease in NFκB signaling leads to the inhibition of autophagy in our 
setting. 
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Figure 5.23. Knock out of BAP31 leads to the decrease in autophagic flux. A. Expression of LC3-
II protein with and without inhibitor of autophagy. Data show the difference between expression 
in treated and not treated cells, which value indicates autophagic flux. B. Expression of p62, 
another indicator of autophagic flux, also with and without treatment with inhibitor of autophagy. 
C. Expression of LC3-II-EGFP via plasmid transfection in mammalian cell. Green dots indicate 
the number of autophagosomes. Data was tested applying one-way ANOVA statistic. 
 
5.2.9 The knockout of BAP31 in cancer cells leads to the decrease in autophagic flux – 
summary. 
In summary, we proved that lack of the interaction between BAP31 and TRA2B leads to the 
increase in the splicing capacity of cancer cells (Figure 5.24.). We hypothesize, that BAP31 
captures TRA2B in cytoplasm, therefore preventing nuclear translocation of this protein. It 
explains that lack of BAP31 results in increase of TRA2B activity what leads to the increase in 
splicing capacity in cells lacking BAP31. Next, increased splicing results in the higher expression 
of PRMT2, which has been shown as one of the genes regulated via Tra2 proteins. Subsequently, 
PRMT2 negatively regulates NFκB signaling, causing the accumulation of IkBα in the nucleus, 
what leads to the decreased activation of NFĸB and in the reduction of autophagy.  
Our discovery introduces a new function of BAP31 in cancer cells. This novel mode of action for 
the first time shows BAP31 as a protein regulating the process of autophagy. Moreover, the 
interaction of BAP31 and TRA2B is not known so far. Therefore, it gives a new point of view on 
BAP31 in respect to the cancer treatment. 
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Figure 5.24. Functional result of BAP31 knockout in cancer cells. BAP31 knockout leads to the 
absence of BAP31 protein, therefore BAP31 and TRA2B cannot interact. It results in increased 
splicing capacity of BAP31 knockout cells. As PRMT2 is one of the proteins which gene is 
regulated via TRA2B activity, increase in splicing leads to the increase in PRMT2 expression. 
PRMT2 is known to enhance nuclear accumulation of IkBα, what results in decreased nuclear 
translocation of NFĸB-p65, what leads to decreased NFĸB signaling pathway. All these events end 
with disturbed process of autophagy. 
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6. DISCUSSION 
6.1 PS89 – A POTENT CHEMO-SENSITIZER 
Chemo-resistance is still the main contributor to chemotherapy failure and relapse, due to cancer 
cells adaptation to chemotherapeutic stress for survival through genetic and epigenetic alterations 
(Zhou et al., 2012).  As one of the mechanisms inducing chemo-resistance of cancer cells is ability 
to avoid apoptosis (Zheng 2017) it is a common approach to combine chemotherapeutics to 
achieve a better effect of anti-cancer therapy (Zhang et al., 2017; Ma et al., 2019). Our work reveals 
PS89 as a very prominent chemo-sensitizer. As shown in the results part, we were able to show, 
that combination of PS89 with commonly used cytostatics results in significant increase in 
induction of apoptosis in comparison to treatment with drugs alone. 
We could show, that the treatment with 25µM of PS89 was not toxic for the cells, but in the 
combination with chemotherapeutics like Etoposide, Vincristine, Daunorubicin or 6-
Mercaptopurine it was highly effective in induction of ER-mitochondrial mediated apoptosis. In 
all used cell lines, we were able to show that the mechanism of induction of apoptosis is consistent. 
Moreover, the EC50 value for each of these drugs was significantly decreased when combined 
with PS89.   
As the used dose of PS89 was sub toxic for the cells, but worked well in combination with other 
drugs, we decided to characterize this substance as a chemo-sensitizer. 
 
6.1.1 Induction of ER-stress by T8 derivative - PS89 
The small molecule PS89 was synthesized as an analogue of T8. Out of six synthesized molecules 
PS89 was shown to have the highest potential in induction of Etoposide mediated apoptosis in the 
Acute Lymphoblastic Leukemia (ALL) cell line Jurkat. In the proteomics analysis it showed to 
target and inhibit the Protein Disulfide Isomerase (PDI) (Eirich et al., 2014). This protein is known 
as a key player concerning the maintenance of ER homeostasis (Zhang et al., 2018). As the ER 
stress is a common reason for the chemo-resistance of cancer cells (Lingjing et al., 2018; Madden 
et al., 2019), ER homeostasis is an attractive target concerning re-sensitization of cancer cells 
(Janczar et al., 2017; Shah et al., 2018; Clarke et al., 2019). However, the approach of silencing 
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PDI revealed, that this protein is not the only target of PS89. Dr. Fabian Koczian in his doctoral 
thesis has shown, that the knockout of PDI does not rescue the effect of combinatorial treatment. 
Therefore, it was necessary to look for another target of the small molecule. Activity Based Protein 
Profiling (ABPP) conducted by group of Prof. Dr. Stephan Sieber (Department of Chemistry, 
Technical University of Munich) characterized BAP31 as another target of PS89 next to PDI, 
which is also connected to the ER homeostasis. Thus, BAP31 and its function became our focus 
in further research. 
Following the function of PS89 targets we asked the question if the ER function is impaired in cell 
treated with PS89 or the combination. We could show, that treatment of leukemic cells with PS89 
alone did not induce any ER stress or Unfolded Protein Response. However, in the combination 
with chemotherapeutics we observed a very prominent increase in signaling connected to disturbed 
ER homeostasis. This indicates, that activation of all the events connected to the ER stress response 
results from the impaired ER function and defect in resolving the stress condition induced via 
treatment with cytostatics (Eirich et al., 2014). 
 
6.1.2 Chemo-sensitization of leukemic cells towards cytostatics – the mechanism of action 
It is well known, that the induction of apoptosis via cytostatics involves the mitochondria-mediated 
mechanism of apoptosis (Chonghaile et al., 2011). Moreover, it is of increasing interest how the 
ER-mitochondrial communication is involved in the cell fate (Shore et al., 2011; Bhat et al., 2016; 
Simmen & Herrera-Cruz, 2017).  
Our work reveals a potential crosstalk between ER and mitochondria triggered via PS89. As 
mentioned above, the conducted ABPP has identified BAP31, next to the PDI, as the target of 
PS89. BAP31 has been described already as the target of caspase-8. Interestingly, caspase-8 is one 
of essential players in apoptosis mediated by the unfolded protein response (UPR), upon chronic ER 
stress (Estornes et al., 2015; Cano-González et al., 2018; Muñoz-Pinedo & López-Rivas, 2018) 
what links ER chaperone function of BAP31 to apoptosis. Reaching to the work of Iwasawa et al., 
we can learn, that the apoptotic stimuli from Etoposide activates caspase-8, what leads to the 
cleavage of BAP31 to its pro-apoptotic form – p20. Activated BAP31 triggers the release of ER 
calcium to cytoplasm, what results in the induction of mitochondrial apoptosis (Iwasawa et al., 
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2011). Therefore, we investigated if this mechanism of action is applicable also for PS89-cytostatic 
induced apoptosis.  
To show what an important role the interaction of caspase-8 and BAP31 plays in the treatment 
with PS89 as the chemo-sensitizer, we investigated the key proteins involved in this signaling 
pathway. We were able to show, that cleavage of Caspase-8 as well as BAP31 in the combinatorial 
treatment led to the prominent calcium release from ER in comparison to the treatment with 
cytostatics alone. The subsequent event was mitochondrial outer membrane permeabilization 
(MOMP), what led to the release of cytochrome c and Reactive Oxygen Species (ROS) to 
cytoplasm. When ROS seems to induce the ER stress in a positive loop, cytochrome c present in 
cytoplasm triggers further apoptotic stimuli (Shore et al., 2011; Grimm, 2012).  
 
6.1.3 The potential of PS89 as a chemo-sensitizer in the treatment of leukemia cells 
We were able to prove, that the addition of PS89 as a chemo-sensitizer next to the commonly used 
cytostatics, significantly decreases the EC50 value of used drug. This supports the idea of 
application of combinatorial therapies to lower the required dose of the chemotherapeutics (Bayat-
Mokhtari et al., 2017). Moreover, as it was shown in the doctoral thesis of Dr. Fabian Koczian, 
applying combination of PS89 and Vincristine re-sensitized Vincristine resistant CCRF-CEM 
cells. Once again, it supports the idea of the application of combinatorial therapies in respect of 
re-sensitization of drug-resistant cancer cells. This is why the potential of this small molecule 
should be further tested in vivo and, in the future, subjected to the clinical trials. 
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6.2 THE FUNCTIONAL RESPONSE TO BAP31 KNOCK OUT IN HEPATOCELLULAR 
CARCINOMA 
Motivated by the success of PS89 combinatorial therapy, we wanted to focus on the function of 
BAP31. As this protein seemed to be not well investigated in the context of cancer, we created a 
stable BAP31 knockout in the murine hepatocellular carcinoma cell line – RIL-175, what gave us 
a tool to investigate the function of this protein. 
However, as shown in the result part, BAP31 knockout had no influence on main functions of 
cancer cells, like proliferation, migration or attachment. To learn more about the protein of our 
interest, we decided to use the Yeast 2 Hybrid (Y2H) approach to identify the interaction partners 
of BAP31. Using this technique, we were able to show a novel association of BAP31 with 
Transformer 2 β homolog (TRA2B). We could confirm the co-localization of these two proteins 
applying confocal microscopy imaging as well as fractionation approach. Moreover, we were able 
to show the interaction between BAP31 and TRA2B in mammalian cells using co-
immunoprecipitation approach. 
 
6.2.1 Transformer 2 β homolog protein – the functional consequences of the lack of 
interaction with BAP31 
Transformer 2 β homolog (TRA2B) is known as the enhancer of splicing as well as the regulator 
of alternative splicing (Dauwalder et al., 1996). Nowadays, TRA2B was also shown to be 
connected to cancer growth and senescence in different types of cancer (Kajita et al., 2016; Chen 
et al., 2018; Satake et al., 2018) as well as connected to neoplasia and metastasis (Best et al., 2013). 
Following the function of TRA2B in the cell, we validated the splicing capability of cells 
expressing and lacking BAP31. We could show, that in cell lines which are not expressing BAP31 
the splicing level is twice amount of the control. Therefore, we concluded that the interruption of 
interaction between BAP31 and TRA2B leads to an increased activity of TRA2B. 
BAP31 was shown as a chaperon protein (Schamel et al., 2003; Ladasky et al., 2006) thus, we 
hypothesize that TRA2B associate with BAP31 in the cytoplasm, where they are both localized, 
what prevents too frequent translocation of TRA2B to the nucleus. If there is no BAP31 in the cell, 
TRA2B can freely migrate to the nucleus where it acts as the splicing factor increasing the splicing 
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capacity of cancer cells. However, we were not able to show the higher expression of TRA2B in 
the nucleus in cells lacking BAP31. It could be, that these changes are not high enough to be shown 
via regular immunoblotting approach. Therefore, the mechanism that leads to the increased 
splicing capacity in cells lacking the interaction between TRA2B and BAP31 needs to be further 
investigated. 
 
6.2.2 Increase in PRMT2 expression due to the increase in TRA2B-dependent splicing 
Transformer 2 (TRA2) proteins play a role in the regulation of pre-mRNA splicing. Human TRA2 
gene has two separate gene paralogs encoding TRA2A and TRA2B proteins (Ghosh et al., 2016). 
Best et al. have identified 53 genes which were regulated via double-knockout of TRA2α and 
TRA2β (Best et al., 2014). Out of those we focused on Protein Arginine Methyltransferase 2 
(PRMT2), which is known to regulate the Nuclear Factor κB (NFκB) signaling. PRMT2 is 
involved in the regulation of NFκB activation via accumulation of IkBα in the nucleus (Ganesh et 
al., 2006; Dalloneau et al., 2011). This accumulation prevents further translocation of p65 to the 
nucleus decreasing the activity of NFκB. 
In the canonical signaling pathway, upon the activation of the NFκB receptor, the signal is 
transduced to the IκB kinase (IKK) complex. The IKK is the core element of the NFκB cascade. 
It is essentially made of two kinases (IKKα and IKKβ) and a regulatory subunit, NEMO/IKKγ 
(Israël, 2010). Subsequently, the Inhibitor of κB (IkB) protein is phosphorylated by IKK, what 
leads to the release of NFκB from the inhibitory complex. Once this transcription factor is free, it 
can translocate to the nucleus and fulfill its function.  
We were able to show, that the expression of PRMT2 is almost four-fold higher in cells lacking 
BAP31. Moreover, applying the nuclear-cytoplasm fractionation we could show, that the 
accumulation of IkBα in nucleus occurs in BAP31 knockout cell lines but not in the wild type. We 
also showed, that the translocation of p65 to the nucleus is lower in cells lacking BAP31, what is 
consistent with increased expression of PRMT2 in those cells. Moreover, we also showed that the 
phosphorylation of IkBα was affected in cells lacking BAP31 expression. All these data prove, 
that NFκB signaling is decreased in cell lines lacking BAP31-TRA2B interaction (Figure 6.1.). 
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Figure 6.1. Influence of lack of BAP31 on NFκB signaling. Lack of interaction between BAP31 
and TRA2B leads to the increase in splicing, what results in increased PRMT2 expression. As 
PRMT2 is a protein which blocks nuclear export of IkBα, it leads to nuclear accumulation of IkBα. 
All these events result in decreased activation of NFκB signaling pathway. 
 
6.2.3 The result of changes in NFκB signaling – decrease in autophagy 
NFκB is a protein involved in carcinogenesis in almost every aspect (Xia et al., 2014; Park & 
Hong, 2016). NFκB can be activated through a broad spectrum of stimuli like growth factors 
(Epidermal Growth Factor (EGF)), lipopolysaccharides (LPS) produced by bacteria, cytokines 
(TNF-α, IL-6, ect.), UV light, reactive oxygen species (ROS), DNA damage or oncogenic stress 
(Xia et al., 2014). 
According to Xia et al. NFκB signaling supports proliferation of cancerous cells, angiogenesis, 
promotes metastasis, influences the metabolism of the cell as well as helps cancer cells to escape 
apoptosis (Xia et al., 2014). Moreover, NFκB signaling has been connected to autophagy, which 
is in a focus of science nowadays (Trocoli & Djavaheri-Mergny, 2011; Zhu et al., 2017). As we 
could not see a difference in proliferation or migration of cells lacking BAP31 expression, we 
decided to investigate a potential role of BAP31 in autophagy.  
To prove that autophagy is affected in our setting, we checked the expression of LC3-II as well as 
p62 with and without treatment with Concanamycin, a known inhibitor of autophagy. Following 
the instructions contained in the article of Zhang et al., we verified the level of autophagy (Zhang 
et al., 2017). Evaluation of both proteins showed that this process is decreased in BAP31 knockout 
cells. We could re-confirm that via overexpression of LC3-II conjugated with GFP. Using confocal 
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microscopy, we showed that the number of autophagosomes is lower in cells lacking BAP31 
expression.  
 
6.2.4 Autophagy as the therapeutic target in cancer 
Autophagy is a process of capturing the intracellular components in autophagosomes and delivers 
them to the lysosomes for the degradation and recycling (Levine & Kroeme, 2008; Mizushima, 
2010). Selective autophagy recognizes, captures and eliminates the unfolded proteins induced by 
stress and damaged organelles. This helps to protect normal cellular components. To ensure, that 
the cargo is recognized properly, it is tagged via ubiquitination. Subsequently, ubiquitin is 
recognized by the autophagy receptors and the cargo is subjected to the autophagy machinery 
(Clague & Urbe, 2010). Under normal conditions, autophagy functions at a constitutive, low basal 
level to maintain protein and organelle quality, quantity, and functionality. However, this process 
is dramatically induced by starvation and other stressors, which enable cellular and organismal 
survival. Autophagy upregulation is part of a survival mechanism under the nutrient stress, which 
is conserved from yeast to mammals (Amaravadi et al., 2016). 
Nowadays, it is known that autophagy has opposing, context-dependent roles in cancer. Therefore, 
both - stimulation and inhibition of autophagy have been proposed as cancer therapies (Levy et 
al., 2017). It was shown, that once cancer is established, increased autophagic flux often enables 
tumor cell survival and growth (White, 2012; Amaravadi et al., 2016). This supports the idea, that 
inhibition of autophagy would be a good therapeutic approach. 
It is important to keep in mind, that many of current cancer treatments are affecting autophagy. 
For example, those which are impairing the mTOR signaling pathway like Rapamycin (Jung et al., 
2010; Paquette et al., 2018).  Also, the physiological changes in cancer environment like hypoxia 
or nutrient depletion have an influence on the autophagy (Levy et al., 2017). Therefore, it is 
impossible to ignore this process in the context of cancer. 
As we shown in our work, knockout of BAP31 leads to the decrease of autophagy in mice 
hepatocellular carcinoma cell line. However, we did not observe any influence of decreased 
autophagy on the proliferation capacity or migratory potential of used cells. This could be 
explained via different roles of autophagy in different types of cancer as discussed above. It would 
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be necessary to investigate the role of BAP31 on the autophagy induction in different types of 
cancer to understand in which setting BAP31 expression would have a survival and therapeutic 
meaning. 
 
6.2.5 The consequences of BAP31 deregulation in different types of cancer 
The role of BAP31 inhibition or overexpression is very controversial. Tan et al. Showed that the 
low expression of BAP31 in human primary hepatocellular carcinoma (Tan et al., 2016) as well as 
in human colorectal cancer (Ma et al., 2018) correlates with poor prognosis. Also, Seo et al. 
showed that the overexpression of BAP31 is connected to poor survival of non-small cell lung 
carcinoma cells (Seo et al., 2017). However, there are also statements, that inhibition of BAP31 is 
supporting cell death and inhibiting cancer growth (Xu et al., 2019) as well as suppressing 
metastasis of malignant cells (Yu et al., 2015; Dang et al., 2018; Wang et al., 2019).  
As mentioned above, autophagy also seems to contribute to the survival, growth and metastasis of 
cancer (Mowers et al., 2017), however depending on the type of cancer inhibition or induction of 
this process can have a different role. The confusion about BAP31 expression in cancer seems to 
be the same. Therefore, the contribution of BAP31 in the process of autophagy could be a missing 
puzzle piece concerning the function of the investigated protein in cancer.  
Our research is first to report involvement of BAP31 in autophagy. Moreover, it introduces a new 
perspective concerning the role of BAP31 and shed a light on its function in cancer cells. 
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7. SUMMARY  
BAP31 is an interesting protein investigated more intensively nowadays. Its function in induction 
of apoptosis has been broadly described in literature. Here, using state-of-the-art molecular biology 
methods, we checked the chemo-sensitizing effect of a small molecule targeting BAP31 – PS89, 
on different leukemia types in combination with commonly used cytostatics and showed very 
prominent results concerning chemo-resistance and induction of apoptosis in leukemia in vitro 
models. Moreover, we were able to confirm the involvement of BAP31 activation in 
mitochondriadriven apoptotic signaling pathway.  
The promising results of combination treatment led us to focus on this interesting protein. From 
the literature it is clear that the induction of apoptosis is not the only influence that BAP31 exerts 
on cancer cells. Therefore, it was of our interest to explore the function of BAP31 in this regard. 
For this purpose, we applied a novel CRISPR/Cas9 technique to create a tool for further 
investigation – a stable knockout of BAP31 in murine hepatocellular carcinoma cell line RIL-175.  
To overcome the next challenge, which was the identification of BAP31 cooperation partners, we 
applied the Yeast Two Hybrid method, which was intensively developed over last years. This 
approach enabled us to identify a novel interaction between BAP31 and TRA2B (a protein engaged 
in splicing). Dual Luciferase Reporter Gene assay allowed us to show increased splicing capability 
of BAP31 knockout cells. The literature review helped to identify the protein regulated via TRA2B 
dependent splicing – PRMT2. We were able to confirm, that the expression of this protein is 
upregulated in cells lacking BAP31. Mitochondrial/nuclear fractionation approach helped to 
confirm that increased expression of PRMT2 led to the accumulation of IkBα in the nucleus, what 
has been described in the literature as the mechanism of action for PRMT2. This accumulation 
potentially inhibits activity of the NFĸB complex what results in decreased autophagy in cells 
lacking BAP31 expression (Figure 7.1).  
Summarizing, we were able to show for the first time the involvement of BAP31 in cellular 
processes like splicing or autophagy, which are known to be changed in various types of cancer. 
Our work shed light on the function of BAP31, what is a starting point for further drug 
development, treatment strategies as well as diagnostic parameter. However, further investigation 
is needed.   
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Figure 7.1. Functional result of BAP31 knockout in cancer cells. Lack of BAP31 leads to the 
increase in splicing capability, what results in increased expression of PRMT2. Activity of PRMT2 
affects the transport of IκBα from nucleus. Accumulation of IκBα potentially interferes with 
NFκBDNA binding affecting its activity. All these events influence autophagy capacity of cells 
lacking BAP31. 
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8. SIDE PROJECT 
Targeting de novo lipogenesis as a novel approach in anti-cancer therapy 
Stoiber K, Nagło O, Pernpeintner C, Zhang S, Koeberle A, Ulrich M,  Werz O, Müller R, Zahler 
S, Lohmüller T, Feldmann J, Braig S. British Journal of Cancer. 2018 Jan; 118(1):43-51;  
doi: 10.1038/bjc.2017.374 
8.1 INTRODUCTION 
Cellular membrane is a very important organelle for each cell. It is not only a selective barrier 
taking part in the maintenance of cell integrity and compartmentalization but also establishes a 
signaling platform for the processes like cellular growth, differentiation or migration (Cooper, 
2000). Therefore, plasma membrane properties are of great interest of science concerning their 
contribution to regulation of malignancy and metastatic abilities of cancer cells (Escriba et al., 
2015). As the ability of cells to deform plays a quite important role in metastatic potential, this 
property was proposed as a marker for migratory capability of cancer cells. It is important to keep 
in mind, that these peculiarities are connected not only to the cellular cytoskeleton but also to the 
membrane characteristics (Remmerbach et al., 2009; Swaminathan et al., 2011). 
So far, all the efforts to target the migratory capacity of the cell focused on the cytoskeleton 
(Rauscher, 2018; Ilan, 2019; Bryce et al., 2019). However, cellular membrane is also of a great 
importance concerning this process. The composition of plasma membrane impacts 
biomechanistic as well as characteristic of the cells (Sherbet. 1989; Nicolson 2015). This has been 
shown before, that the acetyl-CoA carboxylase (ACC) activity, which is a limiting enzyme of fatty 
acid synthesis, can influence the phospholipid composition of cellular membrane, what leads to 
the changes in its composition (Rysman et al., 2010; Braig et al., 2015).  
The aim of this study was to investigate the consequences of disturbing plasma membrane 
physiology by inhibiting ACC. Thereby we investigated of key players of cancer promoting 
signaling pathways and unrevealed the functional impact of ACC inhibition on proliferation of 
cancerous cells. We could contribute to the investigation of molecular basis of targeting the plasma 
membrane properties and introduce it as a promising therapeutic strategy against cancer. 
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8.2 RESULTS 
It was shown in the doctoral thesis of Dr. Katharina Stoiber, that inhibition of ACC activity via 
Soraphen A treatment of the HER2 overexpressing breast cancer cell line SKBR3 led to changes 
in plasma membrane composition. ESI tandem mass spectrometry has revealed that the double-
bonds in cells treated with Soraphen A changes from the less saturated towards more saturated in 
all groups of phospholipids, namely: phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
phosphatidylinositol (PI), phosphatidylserine (PS). Also, it was shown that the chain length of PC 
as well as PE was increased in cells treated with the ACC inhibitor in comparison to the control 
cells. This led to the impairment of the plasma membrane rigidity, what was tested applying the 
Fluorescence Recovery after Photobleaching (FRAP) approach in cells treated with Soraphen A. 
Another approach which used to confirm changes in the membrane stiffness was the vesicle 
deformation measurement conducted via Dr. Carla Pernpeintner from the group of Prof. Dr. Jochen 
Feldmann (Photonics and Optoelectronics Group of Department of Physics and Center for 
Nanoscience, LMU), which re-confirmed the impairment of plasma membrane properties (Figure 
7.1.). 
 
Figure 8.1. A. Experimental setup for vesicle deformation measurements: A single membrane 
vesicle derived from SKBR3 cells was trapped on one end with a focused laser beam (optical 
tweezer). Application of flow results in elongation of the vesicle along the flow direction. Right: 
Dark-field microscopy image of an optically trapped vesicle. The 2D projection of the vesicle is 
fitted with an ellipse using home-built Matlab and C þ þ routines. A dashed line indicates an 
elliptic fit of the vesicle cross-section with half axis a and b. B. Comparison of the maximum 
deformation Dmax of vesicles obtained from cells after treatment with Soraphen A or control. The 
error bars indicate the s.e.m. for a sample size of 30 and 40 cells, respectively. 
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As Dr. Katharina Stoiber also shown in her thesis, changes in cellular membrane composition led 
to the inhibition of interaction between HER2 and EGFR. Activation of these two proteins is an 
important event in signaling which promotes cancer proliferation (Diermeier et al., 2005). She was 
also able to show that the phosphorylation of these proteins is decreased in cells treated with 
increasing doses of Soraphen A.  
Next to the signaling, receptor recycling is another process strongly dependent on membrane 
characteristics. Previous research has indicated that endocytotic recycling of EGFR may be the 
underlying molecular mechanism for its increase (Tong et al., 2017). Therefore, my role was to 
investigate the recycling process in cells treated with Soraphen A as well as upon the silencing of 
ACC1. This experiment could confirm, that treatment with ACC inhibitor led to the disturbance 
in recycling of transferrin receptor. The same effect was observed in ACC1 knockout cells (Figure 
7.2).  
 
Figure 8.2. Impaired recycling of transmembrane receptors. A: Receptor recycling of soraphen A-
treated and B: siACC1-transfected SKBR3 cells was monitored by adding rhodamine-tagged 
transferrin upon the treatment for 72 hours with either Soraphen A or siACC1. 
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Metastasis is the leading cause of cancer related death and thus it is crucial that we improve our 
understanding of the mechanisms that promote this life-threatening phenomenon. Therefore, the 
migratory capacity of cancer cells upon the treatment with Soraphen A was fully investigated via 
Dr. Katharina Stoiber. Next to the metastasis, second important property of cancer cells is 
capability to grow. Thus, my task was to test different inhibitors of ACC and Fatty Acid Synthase 
(FASN), another important player concerning de novo lipogenesis, in context of the proliferation. 
As Soraphen A was shown to effectively inhibit proliferation of SKBR3, we decided to treat them 
with some more ACC inhibitors – TOFA and CP-640,186, as well as FASN inhibitors – Cerulenin, 
C75 and UCM05 to prove, that the reason of impaired proliferation is due to the decrease in de 
novo lipogenesis. Figure 7.3 shows, that all of them could inihibit the proliferation rate of those 
cells. 
 
Figure 8.3. The proliferation of SKBR3 cells is inhibited upon the treatment with different doses 
of both ACC and FASN inhibitors. The proliferation rate was assessed after 72 hours of 
proliferation applying Cell-Titer Blue assay. The error bars show the standard deviation of three 
independent experiments. Significance was tested applying One-way ANOVA. 
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Moreover, we were able to prove, that this function is impaired via change in the composition of 
plasma membrane. We were able to rescue the effect of the inhibition of ACC by Soraphen A 
treatment applying the PI mix to the cells. This is shown in the Figure 7.4. 
 
Figure 8.4. Treatment with PI mix rescued the effect of Soraphen A treatment on the proliferation. 
The error bars show the standard deviation between three independent experiments. Significance 
was tested applying the One-way ANOVA. 
 
8.3 DISCUSSION 
These studies show, that cellular membrane is an attractive target for cancer therapy. Treatment of 
cancer cells with the inhibitors of de novo lipogenesis led to impaired proliferation and migration. 
Dr. Katharina Stoiber could show, that these functions were connected to changes in the plasma 
membrane phospholipid composition, what led to increased membrane stiffness and resulted in 
inhibition of interaction between EGFR and HER2. Impaired signaling led to decrease in 
proliferation and migration of cancerous cells. 
The issue of plasma membrane was already studied in the context of cancer (Zalba & Hagen, 
2017). However, the membrane lipid therapy did not reach the clinic yet, even though it is 
described as a very promising new treatment approach (Escriba, 2017). Following the idea of 
targeting lipid metabolism, it is possible to inhibit a growth of cancer cells. This has been shown 
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for example using Orlistat, which is a fatty acid synthase (FASN) inhibitor, in combination 
therapies (Menendez et al., 2006; Wright et al., 2017). Also, acetyl-CoA carboxylase (ACC) has 
been shown as a good target to inhibit the proliferation of non-small-cell lung cancer in vivo using 
ND-646, an allosteric inhibitor of the ACC enzymes (Svensson et al., 2016). 
To better understand the functional implications of the impaired phospholipid composition of 
cellular membrane, we used Soraphen A, which is a well-known ACC inhibitor, to analyze the 
crucial importance of phospholipid homeostasis on functions of cellular membrane. Even though 
the mechanism of action of this compound was not elucidated in detail so far, there is some data 
unraveling that targeting ACC leads to the changes in phospholipid composition of cellular 
membranes and its dynamics (Rysman et al., 2010). This also has been confirmed by our group 
and these data are available in the doctoral thesis of Dr. Katharina Stoiber. Moreover, in co-
operation with Dr. Carla Perpeinter from the group of Prof. Dr. Jochen Feldmann (Photonics and 
Optoelectronics Group of Department of Physics and Center for Nanoscience, LMU) we could 
show, that treatment with Soraphen A leads to significant increase in stiffness of the membrane 
vesicles in comparison to the control group.  
Cellular membrane is not only a barrier between a cell and environment. It also takes part in the 
signaling, for example via regulation of recycling process (Ray et al., 2016). We could confirm, 
that inhibition of ACC either with Soraphen A or siRNA directed against ACC1, changes the 
recycling of Transferrin receptor. In the doctoral thesis of Dr. Katharina Stoiber as well as in the 
publication of Braig et al. (Braig et al., 2015), it was also shown, that the localization and 
dimerization of the growth factors HER2 and EGFR was impaired upon the treatment with 
Soraphen A. As these two receptors are the important players in the process of cancer growth, 
changes in the membrane composition are affecting their lateral movement, what leads to the 
impaired downstream signaling and inhibition of cancer growth. Therefore, targeting the cellular 
membrane properties would be a promising therapeutic approach in cells where the classical 
compounds targeting growth factors receptors properties are limited due to mutations in the kinase 
domain of the receptor (Kobayashi et al., 2005). Moreover, this effect is amplified via the 
abrogated recycling process. The receptors, when activated, are internalized, sorted at the 
endosomes and, subsequently, they can be either degraded or recycled back to the plasma 
membrane to further promote proliferation. When this process is not functioning properly, the 
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dysregulated EGFR trafficking results in impaired cellular growth and cancer progression (Tomas 
et al., 2014). We could show, that the inhibition of the transferrin receptor recycling, which resulted 
from ACC inhibition, led to the accumulation of the receptor-ligand complex in the juxtanuclear 
area, what interfered with cancer-associated growth factor receptor signaling. 
In summary, the work of Dr. Katharina Stoiber and me shows that altered properties of cellular 
membrane via interrogation of de novo lipogenesis impaired the characteristics of cellular 
membranes like its deformation and fluidity. This led to the decrease in the dimerization of EGFR 
and HER2, diminished receptor recycling capacity of cancer cells treated with ACC inhibitor and, 
finally, inhibition of proliferation. These data show, that targeting the membranes properties via 
inhibition of de novo lipogenesis is a promising approach concerning anti-cancer therapy. 
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